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ABSTRACT OF DISSERTATION 
 
 
 
POTENTIAL CANDIDATES FOR TREATING DEFICITS ASSOCIATED WITH 
DEVELOPMENTAL ETHANOL EXPOSURE IN A RODENT MODEL: SOLIDAGO 
NEMORALIS & DIMETHOXYBENZYLIDENE-ANABASINE 
Prenatal alcohol exposure (Fetal Alcohol Syndrome [FAS] and Fetal Alcohol 
Spectrum Disorders [FASD’s]) represents the leading preventable cause of intellectual 
disabilities in the western world, with FASDs estimated to affect approximately 2-5% of 
live births in the United States at an approximate annual cost of $3.6 billion (CDC, 2015; 
May et al., 2009). Ethanol (ETOH) exposure during development can lead to a variety of 
long-term behavioral impairments including problems with executive functioning, motor 
coordination, spatial learning, attention, and hyperactivity (Jones, 2011; Mattson & Riley, 
1998). Much research has been conducted to develop pharmacological and/or 
environmental interventions to reduce these deficits, however, there are currently no 
clinically approved medications to treat the deficits related to fetal ETOH exposure. The 
current study used a developmental “3rd trimester” ETOH exposure model in neonatal 
rats to test the hypothesis that compounds targeting the nicotinic system will reduce 
deficits associated with ETOH exposure. Both compounds demonstrated promise in 
reducing some of the effects of developmental ethanol exposure, with DMXB-A 
treatment after ethanol exposure reducing balance deficits in females and spatial memory 
deficits in males. Solidago nemoralis treatment after ETOH exposure reduced learning 
and memory deficits in males and balance and executive functioning deficits in both 
sexes. With these results and previous work in this lab and others there appears to be 
ample evidence for their usefulness in reducing various forms of neurotoxicity. The long-
term goal of this research is to evaluate the usefulness of both DMXB-A & Solidago 
nemoralis (SN) in treating deficits related to developmental ETOH exposure in humans 
and hopefully develop a treatment for these disorders.  
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Chapter 1: 
Overall Introduction 
Ethanol Use, Abuse, and Outcomes 
 Excessive alcohol consumption remains an issue in western civilization with 
approximately 25% of the population (18 years or older) reporting a binge drinking 
episode in the last month (NIAAA, 2017). Alcohol use among pregnant women in the 
United States was estimated to be at 15% while binge drinking during this same period 
was around 3% (Popova, et al. 2017). Consuming ethanol (ETOH) during pregnancy can 
have numerous negative consequences for the developing fetus including Fetal Alcohol 
Syndrome (FAS) or Fetal Alcohol Spectrum Disorder (FASD). The syndrome itself was 
first clinically described in France in 1968 by Lemoine and colleagues (Lemoine et al., 
1968) and then later (1973) in America by Jones & Smith (Jones & Smith, 1973). FAS is 
diagnosed using a characteristic set of facial anomalies including: short palpebral 
fissures, abnormalities in the premaxillary zone (including a flat upper lip, flattened 
philtrum, and flat midface), evidence of pre/post-natal growth retardation (low birth 
weight, failure to thrive), and finally evidence of central nervous system (CNS) damage 
(microcephaly, intellectual disability, or neurobehavioral deficits) (Stratton, 1996). As 
understanding of the disorder increased researchers eventually described a spectrum of 
disorders – Fetal Alcohol Spectrum Disorders (FASD’s) caused by ethanol exposure 
during fetal development with FAS being the most severe. Importantly, the guidelines for 
identifying FASD is that children do not have to demonstrate all of the characteristic 
symptoms found in FAS to be identified as being affected by prenatal ethanol exposure 
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(Jones, 2011). Broadening the category of those individuals affected by prenatal ethanol 
exposure may help families and children that may not have all of the facial abnormalities 
affected by the disorder receive the potential help they need and lead to the development 
of pharmacotherapies aimed at treating or eliminating these disorders before or after they 
occur. As of 2016 the clinical guidelines for diagnosing FAS and other disorders relating 
to developmental ETOH exposure were revised in an effort to increase sensitivity to the 
disorder (Hoyme, et al. 2016). Within these new guidelines children believed to be 
affected by prenatal ETOH exposure must demonstrate evidence of neurobehavioral 
impairment including deficits in global intellectual ability (full-scale, verbal, performance 
or spatial IQ), cognition (executive functioning, learning, memory, visual-spatial skills), 
behavior and self-regulation (mood, behavioral regulation, attention, and impulse 
control), and adaptive skills (Hoyme, et al., 2016). In response to these new guidelines, 
prevalence of the disorder has now been conservatively estimated to be around 1-5% of 
first-grade children (May, et al. 2018). Interestingly, this study also suggests that 
underdiagnosis or missed diagnosis is incredibly high, of the over 6000 children they 
investigated 222 were diagnosed with prenatal ethanol effects by their clinicians, 
however, only 2 of them were previously diagnosed (May, et al. 2018). Individuals living 
with FAS/FASD typically express some behavioral/learning deficits and often experience 
social/economic difficulties later in life (Bishop et al., 2007). Common behavioral 
deficits associated with developmental ETOH exposure include issues with executive 
functioning, cognitive flexibility, motor coordination, working memory, spatial learning, 
attention, and hyperactivity (Jones, 2011; Mattson et al., 2010; Mattson & Riley, 1998). 
FAS/FASD remains the leading preventable cause of intellectual disabilities in the 
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Western World and healthcare and other indirect costs associated with the disorder are 
estimated to be as high as $4 billion annually in the US alone (Olson, et al. 2009; Hoyme, 
et al. 2016).    
ETOH’s effects on the brain: 
 The developing fetus is in a constant state of growth which encompasses the 
development of the central and peripheral nervous systems. These systems are highly 
susceptible to the neurotoxic effects of ethanol during their development.  Some of 
ethanol’s effects on the CNS include: disruption in cellular metabolism, an increase in 
hypoxic events, the creation of free radicals, neuroinflammation, excitotoxicity, an 
inhibition of DNA methylation, and membrane fluidization (For review see: Alfonso-
Loeches & Guerri 2011; Berman & Hannigan 2000; Goodlett & Horn, 2001 & 2005; 
Jones 2011, Olney, J. 2004; West et al., 1994). These various mechanisms of damage 
lead to disruption of brain development and subsequent cognitive, motor, and behavioral 
functions in almost every region of the brain (for review see Moore et al., 2014). In a 
human study conducted by Chen and colleagues (2011), they reported that absolute 
volume of nearly every region of the brain was significantly reduced in young adults who 
were exposed prenatally to ethanol and that certain regions appeared to be more affected 
by higher levels of ethanol including the corpus callosum, cerebellum, and frontal areas. 
This loss is seen in both grey and white matter when compared to control individuals 
(Lebel et al., 2011; Archibald et al., 2001). The corpus callosum, a structure crucial to 
interhemispheric communication, appears to be one of the most highly affected structures 
in the CNS with complete agenesis of this structure being reported in a number of severe 
cases of FAS (Moore et al., 2014).  Additionally, imaging studies using young children 
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diagnosed with FAS have shown dramatic changes in volume to the hippocampus, a 
structure critical to learning and memory (Archibald et al., 2001; Riley & McGee, 2005). 
Moore (2014) said this loss in volume and change of shape in the hippocampus has been 
highly correlated with deficits in spatial recall and learning. In animal models of 
developmental ETOH exposure, studies using in-vitro hippocampal cultures have shown 
that ETOH exposure followed by withdrawal in the hippocampus drastically reduces 
survival of the cells in several regions of the hippocampus (Barron et al., 2008; de Fiebre, 
2003 & 2005, Li et al., 2000 & 2002; Prendergast et al., 2000 & 2004; Wilkins et al., 
2006). Much of the basal ganglia, important for a variety of functions including 
procedural and habit learning, movement, emotion, and cognition, is significantly 
reduced in volume after developmental ETOH exposure when compared to control 
individuals (Mattson et al., 1996; Archibald et al., 2001; Lebel et al., 2011).  This is 
particularly true with the caudate nucleus and putamen (Chen et al., 2011). Within the 
frontal lobe, an area that controls executive function and control, there is a loss in white 
matter, grey matter, and total lobe volume when compared to controls (Lebel et al., 
2011). The prefrontal cortex appears to be particularly sensitive to developmental ethanol 
exposure resulting in decreased cell volume as a result of apoptosis that persist into 
adulthood (Ikonomidou et al., 2001).  This decrease in cell volume in the prefrontal 
cortex could lead to reductions in connectivity with other subcortical structures leading to 
behavioral deficits, particularly cognitive function (Gorsky & Klinstova 2017). Within 
the sub-regions of the frontal cortex, a review by Coles and colleagues (2011) using 
fMRI data showed that activity is decreased compared to controls in individuals with 
FASD as executive functioning tasks become more difficult. Another structure that 
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undergoes significant cell loss is the cerebellum (Coles et al., 2011).  Within the 
cerebellum, a structure critical for its role in movement and coordination, researchers 
have found significant reduction in total volume (Archibald et al., 2001). Interestingly, 
reductions of volume in these structures often correlate to the behavioral deficits most 
often found in FAS/FASD, this has also been found to be true of rodent models as well 
(Schneider, et al., 2011; Jones, et al., 2011; Mattson et al., 2010; Mattson & Riley, 1998). 
 As a consequence of structural alterations produced by developmental ETOH 
exposure there are also many deficits in cognition and behavior. One of the more 
common behavioral deficits found in human populations exposed to ETOH during 
development is hyperactivity and inattention (Jones et al., 2011). Often, individuals with 
prenatal ethanol effects are diagnosed with ADHD (Mattson et al., 2011).  Another deficit 
commonly found in those individuals with FAS/FASD’s is executive function or higher 
cognitive processes (Riley et al. 2011; Jones et al., 2011). Executive function involves the 
frontal lobe which sends projections to the basal ganglia, amygdala, hippocampus, and 
thalamus (Vertes, 2006; Quirk et al., 2003). These structures and networks are 
responsible for integration and regulation of many complex signals (Miller & Cohen, 
2001).  The amygdala, for example, helps regulate attention to fear and anxiety and other 
stressors (Yin et al., 2006), while the basal ganglia regulates motivated learning and goal-
oriented behaviors (Pourtois et al., 2013), with the hippocampus being responsible for 
spatial processing and memory formation (Bannerman et al., 2004). Together, these 
integrated structures allow an organism to attend to specific stimuli, problem-solve, and 
maintain goal-oriented behavior, which is a large part of many complex (like planning, 
response inhibition, and working memory) and basic behaviors (attention, memory, 
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sensation, perception, and motor activation) affected by prenatal ETOH exposure 
(Mattson, et al., 2011).  One aspect of executive function that is of interest in the current 
project is concept formation and set-shifting ability. In children exposed to ETOH during 
development their ability to complete the Wisconsin Card Sorting Test (WCST, a test 
designed to test concept formation and set-shifting ability) was significantly lower than 
control children (McGee et al., 2008). It also appeared that individuals with a diagnosis 
of FAS or those exposed to developmental ETOH but not FAS showed similar levels of 
deficits relative to controls (McGee et al., 2008). Along with deficits in set-shifting 
ability, many children exposed to prenatal ETOH also had trouble with inhibitory control, 
as measured on the Stroop Test (Mattson et al., 1999). For working memory, a function 
largely controlled by the hippocampus as well as other structures including the basal 
ganglia and frontal lobe, children exposed to ETOH were deficient at a Digit Span test 
when compared to control children (Burden et al., 2009). Additionally, spatial working 
memory was impaired in children and adults exposed to prenatal ETOH (Green et al., 
2009).  Regarding motor function, controlled largely by the cerebellum, it appears that 
children with FASD or FAS have deficits in postural stability, gait, motor reaction time, 
fine motor speed and coordination, timing, hand eye coordination, goal directed 
movements, and sensory processing and performance (see Mattson et al., 2011 for 
review). As reviewed by Schneider and colleagues (2011) and discussed later, animal 
correlates of these behaviors have been demonstrated using many different models. 
Within these models, animals exposed to developmental ETOH have shown similar 
deficits as the human population in all of the above-mentioned behaviors including 
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attention, learning, memory, executive function, and motor function (Riley et al., 2005; 
Mattson, et al., 2011; Thomas et al., 2004; Waddell et al., 2017).  
Modeling FAS/FASD 
 Although the exact pattern, timing, and dose of ETOH exposure required for 
adverse outcomes is still relatively unknown, it appears that these factors do play a 
critical role in the development of FAS/FASD. First, alcohol readily crosses the placental 
barrier which causes the unborn fetus’s blood alcohol content (BAC) to rapidly elevate to 
that of the mothers (Painter, 2012). During development, the fetus does not possess the 
necessary enzymes (alcohol dehydrogenase [ADH] and cytochrome P450 2E1 
[CYP2E1]) of alcohol until later in pregnancy (CYP2E1 at week 16 on and ADH at week 
26 on) and even after these metabolites are present, they are not as effective as that of 
adults which cause extended ethanol exposure (Ehrhart et al., 2018). Research in rodents 
related to dose has shown that moderate to high levels of ETOH exposure (ranging from 
100-400mg/dl) can reliably produce neurotoxicity and adverse behavioral effects, but 
much of this is often dependent on pattern of drinking as well (for review see Patten et 
al., 2014).  Binge exposure followed by a period of withdrawal led to greater elevations 
in peak BAC’s and greater neurotoxicity than other patterns of drinking (Livy et al., 
2003).  In clinical populations this pattern of binge drinking followed by periods of 
withdrawal has been linked to more severe deficits in children with FASD’s (Painter et 
al., 2012). This pattern of drinking (short periods of both binge and withdrawal) is very 
common in individuals with an alcohol use disorder (AUD) (Painter et al., 2012).  
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The timing of ETOH exposure is also critical when considering the consequences 
of developmental ETOH exposure. Because mammals have a strikingly similar CNS 
developmental trajectory it makes comparison between species easier for investigating 
the effects of developmental ETOH exposure (Patten et al., 2014). They go through 
massive amounts of neural cell generation, migration, proliferation, and cell death during 
critical periods of development (Goodlett et al., 2005). A significant period of brain 
growth referred to as the “brain growth spurt” occurs in humans during the 3rd trimester 
and extending shortly after birth while in rodents the equivalent period is the first weeks 
after birth (Dobbing & Sands, 1979). Because this growth spurt occurs postnatally in 
rodents, it presents a great opportunity to manipulate and investigate this sensitive period 
with a high level of control that might be impossible in utero. Though many deficits both 
physiological and psychological have been reported in models focusing on the rodent 
prenatal ETOH exposure model (1st and 2nd trimester human equivalent), the rodent 
postnatal ETOH exposure model (3rd trimester human equivalent) which overlaps with 
the brain growth spurt seems to be particularly sensitive to the teratogenic effects of 
ETOH exposure (Barron et al., 2016; Goodlett et al., 1997; Riley et al., 1993). Indeed, 
model’s focusing on this period of CNS development have reliably found deficits in 
motor coordination (Idrus et al., 2011; Lewis et al., 2007; Thomas et al., 2004), 
attention/activity (Smith et al., 2012; Thomas et al., 2007; Lewis et al., 2012), learning 
and memory (Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012), and executive 
function (Thomas et al., 2000). These deficits are not surprising however because the 
structural deficits caused by ETOH exposure during the third trimester appear to have 
significant effects on the cerebellum, hippocampus, and prefrontal cortex; all structures 
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that undergo significant growth during the first weeks after birth and are involved in these 
behaviors (for review see Dobbing & Sands, 1979; Riley & McGee, 2005 & Patten et al., 
2014).  Though drinking during the third trimester is low (as low as 2.5% of women who 
drink during pregnancy reported drinking during the third trimester [CDC, 2016]), 
targeting this period in animals is beneficial to further our understanding of ETOH’s 
effects on the developing brain and how treatment with various compounds may prevent 
this damage.  
ETOH’s Mechanism of Damage & Potential Targets for Treatment  
 Ethanol’s effects on the brain are diverse and so too are the mechanisms in which 
it damages the brain (disscused in depth by Alfonso-Loeches & Guerri 2011). ETOH has 
an overall inhibitory effect on CNS function by increasing binding capacity and 
potentiating the action of the inhibitory neurotransmitter GABA at the type-A GABA 
receptor subunit and also type 1 glycine receptors (Reviwed in Proctor et al., 2006). 
Exposure to ETOH also inhibits function of glutamatergic N-methyl-D-Aspartate 
(NMDA) and influences synaptic clustering of these receptors (Kalluri, et al., 1998; 
Ticku 1980). With prolonged exposure the brain adapts to restore homeostasis by 
upregulating NMDA receptor density and/or function. When alcohol is removed from the 
system withdrawal is initiated and the system goes into a state of neuronal 
hyperexcitability due to the increased expression/function of the NMDA receptors along 
with a release of inhibition by the GABA’ergic receptors (reviewed in Hoffman et al., 
1990 & Hunt, W. 1983). In addition to ETOH’s general effects on GABA and glutamate, 
it appears ETOH can potentiate serotonin type-3 (5-HT3) receptor function, inhibits or 
stimulates 5’-triphosphate-gated purinergic receptors, and also decrease agonist binding 
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affinity (Hendricson et al., 2007; Proctor et al., 2006). Exposure to ETOH also appears to 
enhance ACh-evoked currents specifically from nicotinic receptors (Covernton & 
Connolly 1997). Calcium flux through voltage-gated ion channels declines with 
inhibition by ETOH exposure which can lead to downstream effects discussed later 
(Proctor et al., 2006). Some of the specific effects of ETOH, as mentioned above, depend 
on the stage of development and when ethanol is on board. ETOH can have varying 
effects on cell proliferation, migration, growth, and differentiation in various regions of 
the brain. In early development (embryonic stage) for instance, the reduction of retinoic 
acid (a critical regulator of the Hox gene which directs bodily growth) caused by 
ethanol’s competitive binding on ADH, appears to play a role in neural crest death and 
defects throughout the brain (Alfonso-Loeches et al., 2011). Also, ethanol exposure 
during early and later brain development can disrupt the production of critical 
neurotrophic factors (which support cell survival and maturation). Indeed, brain-derived 
neurotrophic factor (BDNF, responsible for neural survival and synaptic plasticity) and 
its receptor TrkB (tyrosine kinase receptor, which activates PI-3-K/Akt and extracellular 
signal-regulated kinases [ERK] pathways which stimulate cell survival transcription 
factors) are lowered by ethanol exposure leading to cell death (for review see Climent et 
al., 2002).  Ethanol also appears to disrupt growth factors related to cell-cycle events 
(specifically cyclin-dependent kinases) and insulin-like growth factor (IGF) involved in 
cell differentiation and proliferation respectively (Alfonso-Loeches et al., 2011).  
Additional effects of ethanol on the developing brain include reduction of neural cell 
adhesion molecules (NCAM’s) critical for cell-cell interaction and brain organization by 
participating in cell migration, morphogenesis, synaptogenesis and synaptic plasticity in 
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the brain (Shapiro et al., 2007; Alfonso-Loeches et al., 2011).  Ethanol also appears to 
promote caspase-3 activation (a protease involved in apoptosis) through inhibition of N-
methyl-D-aspartate receptors (NMDAr’s) and GABA’ergic activation which can lead to 
cell death in the developing brain (Olney et al. 2002). Glial formation and development, 
which plays an integral part in migration of young neurons in early development, 
formation of healthy synapses, regulation of neurotransmitter and energy levels, 
plasticity, cell to cell communication (through oligodendrocytes and myelin formation), 
and neuroimmune function also appear to be altered by ethanol exposure during 
development (see Alfonso-Loeches et al., 2011 for review).  
With this evidence there are many potential targets for treating the effects of 
developmental ETOH exposure. One particularly promising direction for potentially 
reducing or eliminating the development of FAS/FASD could be treating the toxicity 
associated with ETOH withdrawal (EWD). ETOH has an overall inhibitory effect on 
CNS function by increasing binding capacity and potentiating the action of the inhibitory 
neurotransmitter GABA at the type-A GABA receptor subunit. With prolonged exposure 
the brain adapts to restore homeostasis by upregulating NMDA receptor density and/or 
function. When alcohol is removed from the system withdrawal is initiated and the 
system goes into a state of neuronal hyperexcitability (reviewed in Hoffman et al., 1990 
& Hunt, W. 1983). Withdrawal from ETOH in the neonate is severely damaging to the 
CNS and produces many deficits demonstrated both in cellular (de Fiebre et al., 2003; Li 
et al., 2004; Prendergast et al., 2000 & 2004) and in-vivo models (Barron et al., 2008, 
Goodlett & Horn 2001; Thomas et al., 1997). This ETOH withdrawal induced damage is 
thought largely to be caused by neuroinflammation (Cantacorps et al., 2017), 
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excitotoxicity (Guizzetti et al., 2014), and oxidative stress (Bondy, 1992).  ETOH 
exposure appears to be linked to the release of pro inflammatory lipopolysaccharide 
(LPS) which activates neuroimmune cells and microglia that can lead to 
neuroinflammation and cell death (Lutz, 2015). This process can also cause the excess 
buildup of reactive oxygen species (ROS) leading to oxidative stress (Lutz, 2015). 
Oxidative stress can also occur in cells in response to a buildup of ROS as a consequence 
of ETOH metabolism, which is particularly true when excessive amounts of ETOH are 
present (Ehrhart et al., 2018; Bondy, 1992). ROS oxidizes lipids, proteins, and other 
metabolites and can lead to DNA damage which can trigger apoptosis. These apoptotic 
events triggered by ROS are correlated to brain volume loss and abnormalities of cortical 
structures which lead to deficits in cognition and behavior (Ehrhart et al., 2018). The 
adult and especially developing brain is particularly sensitive to ROS mediated damage 
because of its high concentrations of unsaturated fatty acids, high oxygen consumption, 
reduced anti-oxidant concentration, and presence of metals catalyzing free radical 
formation (Alfonso-Loeches et al., 2011). Excitotoxicity is believed to occur because of 
the upregulation of the glutamatergic NMDAR’s (a magnesium blocked ion channel that 
regulates calcium entry into the cell) and changes to their subunit composition in 
response to elevated levels of ETOH exposure that makes the receptors hypersensitive to 
excitatory signaling (Smothers et al., 1997). In a normally developing brain NMDAR’s 
are involved in neuronal differentiation, cell survival, neuronal migration, 
synaptogenesis, structural remodeling, long-lasting forms of synaptic plasticity and 
higher cognitive functions (for review see Costa et al., 2000).  ETOH withdrawal induces 
glutamate release which then leads to overactivation of the upregulated NMDAR’s and 
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eventually to excitotoxicity (Rossetti et al., 1999; Prendergast et al., 2004). Additionally, 
this process leads to a buildup of excess calcium intracellularly which can also lead to the 
buildup of ROS which can cause cell death (Lutz, 2015).   
Many compounds have been investigated using in-vitro models for their ability to 
reduce one or several of the damaging mechanisms discussed above with varying levels 
of success. Many studies have focused on reducing glutamate activity to try to reduce the 
effects of excitotoxicity as described above. One of the first studies investigating toxicity 
related to the glutamatergic system discovered that when antagonized, the NMDA 
receptor (with MK-801 [dizocilpine], a noncompetitive antagonist which binds inside the 
magnesium channel preventing calcium flow) during EWD, there is a reduction in cell 
death and behavioral deficits (Thomas et al., 1997). Interestingly, it also appeared that 
this neuroprotection produced by MK-801 resulting in NMDAR blockade only occurred 
during EWD (Thomas et al., 2001). This may mean that NMDAR blockade is only 
effective during periods of withdrawal. Additional studies looking at the NMDAR 
showed that MK-801 and ifenprodil (NMDA antagonist at the NR2B subunit which 
prevents receptor activation) reduce neurotoxicity and calcium entry produced by EWD 
in organotypic hippocampal slices (Mayer et al., 2002). Memantine (a noncompetitive 
antagonist to the NMDAR and partial agonist to the α7-nAChR) was also able to reduce 
EWD induced neurotoxicity in a similar organotypic hippocampal slice culture model 
(Stepanyan, et al., 2008). Another route for treatment is targeting polyamines (spermine 
and spermidine), which appear to be complex modulators of the NMDAr’s.  Polyamines, 
whose levels are elevated during EWD, lead to increased activation of the NMDAr’s and 
so are correlated with EWD induced neurotoxicity. Reduction of polyamine activity by 
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ifenprodil reduced the damaging effects of EWD both in vitro and in vivo models (Barron 
et al., 2008; Barron et al., 2016). Other treatments have focused on the negative effects of 
oxidative stress caused by ETOH exposure. As mentioned above, ETOH damaging 
effects are thought to be produced by several methods including oxidative stress and the 
buildup of ROS. Antioxidants are believed to be able to reduce the effects of 
developmental ETOH exposure (for review see Cohen-Kerem & Koren 2003). 
Supplements like ascorbic acid (vitamin C) or Vitamin C in combination with Vitamin E 
can reduce some of the effects of prenatal ETOH exposure in a number of in vivo and in 
vitro models (Peng et al., 2005). Even with this research there is still not a clinically 
approved medication for treatment of development ETOH exposure. Because of this, it is 
clear that further work needs to be completed. Development of a compound aimed at 
reducing the damage associated with EWD is appealing because it is potentially a one-
time treatment that would protect the fetus or newborn after ETOH has left the system.  
Cholinergic System 
 One neurotransmitter system that has shown great potential for possibly treating 
the toxic effects of developmental ETOH exposure is the cholinergic system. The 
cholinergic system is one of the most commonly studied systems in the nervous system 
and responds endogenously to the neurotransmitter acetylcholine (ACh). Acetylcholine is 
synthesized by choline acetyltransferase (ChAT) using both choline and acetyl CoA by 
(Abreu-Villaca et al., 2011). The expression of ChAT during brain development is 
commonly used to indicate the location and development of the cholinergic system 
(Lauder & Schambra, 1999). In rats ChAT immunoreactive cells appear 1-2 days 
following generation of neurons from dividing progenitor cells, however the rat brain 
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does not reach adult levels of ChAT reactivity until over a week after birth, depending on 
the structure (cortex & hippocampus is 10 days post-natal development (PND) and PND 
25 for most other structures) (Abreu-Villaca et al., 2011). During early development ACh 
is first detected in the medial septum, diagonal band, and magnocellular preoptic regions 
but as development continues, ACh can be found in target locations like the hippocampus 
and cortex. Along with this it appears that early ACh signaling along with nerve growth 
factor (NGF) may help growing cholinergic neurons find their way to their target 
destination (Abreu-Villaca et al., 2011).  In adult brains, the primary source of ACh is 
from projection neurons (found in the pedunculopontine nucleus, laterodorsal tegmental 
areas, medial habenula, and basal forebrain) and interneurons (found throughout the 
striatum, nucleus accumbens, and to a lesser extent the neocortex) (Picciotto et al., 2012). 
In the CNS, the cholinergic system is thought to change neuronal excitability, alter 
presynaptic release of neurotransmitters, and coordinate firing of groups of neurons (for 
review see Picciotto et al., 2012). Along these lines, ACh is thought to be a facilitator and 
or modulator of many behaviors including processes related to wakefulness and attention 
and is also thought to play a critical role in both learning and memory (Hurst et al., 2013). 
ACh acts on two distinct types of receptors, the nicotinic ACh receptors 
(nAChR’s) and muscarinic ACh receptors (mAChR’s). These ACh receptors play roles in 
the modulation of cell proliferation and survival, neuronal differentiation, regulation of 
gene expression, synapse formation and maturation, axonal pathfinding, and 
neurotransmitter release (For review see Abreu-Villaca et al., 2011). For purposes of the 
current dissertation, the focus will be on the role of the nicotinic system. 
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Nicotinic Receptor System 
The nicotinic receptor system is named so because of its high affinity for nicotine 
(the major psychoactive compound commonly found in tobacco). These receptors were 
the first membrane receptor proteins identified in the 1970s (Dani, 2001). Nicotinic 
receptors are among the first proteins to appear in the developing brain, and some of the 
receptors subunits can be found as early as embryonic day 7 (Atluri et al., 2001). Deficits 
in nicotinic receptors, have been implicated in several neurological disorders including 
Alzheimer’s disease, Parkinson’s diseases, and Down’s syndrome (Dineley et al., 2015; 
Levin, 2002). They fall into a class of ligand-gated ion channels that respond 
endogenously to acetylcholine or exogenously to nicotine (Dani, 2001; Pauly et al., 
2004). The function and location of the receptor in either the CNS or peripheral nervous 
system (PNS) is dependent upon the type and arrangement of its subunits. The nicotinic 
receptor is made of five membrane-spanning regions; each of the five constituent regions 
is composed of different or similar subunits (Wu & Lukas, 2011). The subunits that form 
nicotinic receptors in neural tissue include alpha (2-10) and beta (2-4); these subunits can 
be arranged in many different conformations that are either heteromeric (alpha2-alpha6 
and beta2-beta4), or homomeric (alpha7-alpha9) (Alfonso-loeches et al., 2011; Dani, 
2001). The major subtypes found in the CNS are the alpha4-beta2 heteromeric nAChR’s 
and the alpha7 homomeric nAChR’s (Dani, 2001). On neurons, the role the nAChR’s 
play in the CNS are thought to be largely modulatory because they are often dispersed 
and non-centralized along neuronal membranes of the cell body, presynaptic terminals, 
and even axons (Picciotto et al., 2012). They modulate the release of glutamate, GABA, 
DA, ACh, norepinephrine, and serotonin depending on their location and the subunits 
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they are composed of (for review see Dineley et al., 2015). Recent evidence has also 
demonstrated some nAChR’s are also found on glial cells (astrocytes, macrophages, 
microglia) throughout the nervous system and play a role in modulation of immune 
response which can be protective of events like neuroinflammation, oxidative stress, and 
plaque formation (Suzuki, et al. 2006), discussed further below. These receptors are 
found throughout the brain, including the location of ACh cell bodies as discussed above, 
and sites of their projections including the areas that are most affected by developmental 
ETOH exposure including the frontal cortex, hippocampus, cerebellum (For review see 
Hurst et al., 2013). Activation of neuronal nicotinic receptor system has demonstrated 
efficacy in protection of cells from a variety of toxic challenges, including brain injury, 
oxygen-glucose deprivation, oxidative stress, β-amyloid toxicity, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) kainite and glutamate toxicity, ethanol exposure, and 
nerve growth factor (NGF) deprivation (reviewed extensively in Benchreif et al., 2014).  
α7 nAChR 
Of particular interest to the current dissertation is the α7 nAChR; this receptor is 
of interest to the current study because of its high concentration in areas associated with 
FAS/FASD’s including the hippocampus, prefrontal cortex, and cerebellum (Dani, 2001; 
Hurst et al., 2013). The α7 nAChR is highly permeable to calcium, and is responsible for 
fast postsynaptic transmission, the modulation of release of numerous transmitters, and 
long-term potentiation in various areas throughout the brain (Hurst et al., 2013; Dani, 
2001). During development, the α7 nAChR is thought to be involved in regulating neural 
growth, differentiation and synapse formation through second messenger systems 
activated by calcium entry into the cell (Abreu-Villaca, et al., 2011). This receptor has 
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been given considerable attention recently and is being investigated for its potential 
activation/modulation to treat the multifaceted causes/effects of many neurological 
diseases and disorders (for review see Bencherif et al., 2014).  
In neurons, these receptors are located on the cell at the axon terminal, the pre-
terminal (region just before the terminal that can affect several terminals at once), and the 
postsynaptic dendritic membrane (Albuquerque et al., 2009). This receptor has also been 
found in many non-neuronal cells as well including the macrophage, astrocyte, and 
microglia, which seem to play a part in reducing neuroinflammation (Suzuki et al., 2006; 
Wang et al., 2003; Xiu et al., 2005; Shytle et al., 2004). Previous studies have shown that 
activation of the α7 nAChR has shown considerable promise in reducing excitotoxicity, 
neuroinflammation, and oxidative stress (Benchrief et al., 2014; de Jonge & Ulloa, 2007; 
Prendergast et al., 2000 & 2001; Li et al., 1999). α7 nAChR’s role on microglia, when 
activated, reduce microglial activation and reduce LPS-induced TNF-alpha release 
(Suzuki et al., 2006; Shytle et al., 2004). Activation of the α7 nAChR has also been 
shown to reduced LPS-induced TNF-alpha release in an in-vitro model of EWD in the 
hippocampus of neonatal rodents (Lutz et al., 2015 a & b). The internal mechanism for 
the α7 nAChR modulation of inflammatory response in these cells remains unclear. 
However, several studies have postulated that activation of the receptor creates a 
neuroprotective state in the microglia and in turn reduces transcription and 
phosphorylation of critical components required for activation of an inflammatory 
response like nuclear factor kappa-b, and mitogen-activated protein kinase (see Lutz, 
2015 & Suzuki et al., 2006 for review).   
19 
  
Nicotinic agonists that target the α7 nAChR have also been shown to reduce 
glutamatergic excitotoxicity as well as EWD induced excitotoxicity. Dajas-Bailador and 
colleagues (2000) demonstrated that reduction in NMDA-induced toxicity was modulated 
by the α7 nAChR because co-exposure with MLA (an α7 nAChR antagonist) blocked the 
protective effects of nicotine. Activation of the α7 nAChR has also been directly linked to 
reducing EWD related toxicity in PC12 cell lines, primary hippocampal cultures and in 
organotypic hippocampal cultures (Prendergast et al., 2000 & 2001; de Fiebre et al., 2003 
& 2005; Yangxin et al., 2002). Again, the exact mechanism with which activation of the 
α7 nAChR reduces excitotoxicity is not clear. One theory proposes that activation of the 
α7 nAChR increases calbindin-D28K (a calcium buffer) activity which in turn reduces 
intercellular calcium and increases cell survival (Mullholland et al., 2003). Another 
interesting possibility is through cross-desensitization with the NMDAR. Activation of 
the α7 nAChR by donepezil hydrochloride appeared to mediate phosphorylation and 
subsequent internalization of specific NMDAR receptor subunits preventing 
excitotoxicity (Kihara et al., 2010). However, it is believed that these mechanisms do not 
work in an exclusive manner, instead, it appears that the combination of anti-
inflammatory signaling along with modulation of the NMDAR works together to reduce 
cell death in the CNS (Lutz et al., 2015).  
Additional support for the activation of the α7 nAChR reducing the deleterious 
effects of developmental ETOH exposure stems from choline supplementation. Choline, 
a chemical precursor to acetylcholine and an essential nutrient that targets the α7 nAChR 
nicotinic receptor has shown great promise in reducing ETOH’s deleterious effects. There 
are many published reports demonstrating choline’s effectiveness in reducing ETOH 
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related deficits in learning and memory (Thomas et al., 2000), attention (Monk et al., 
2012; Thomas et al., 2004), balance (Thomas et al., 2009), and executive function 
(Mooney & Waddell et al., 2017, Thomas et al., 2004). In humans, when pregnant 
mothers who had consumed ETOH were given a choline supplementation their babies 
demonstrated less of the adverse effect of prenatal ETOH exposure including reduced 
postnatal growth and cognitive deficits when compared to the babies of women given a 
placebo during pregnancy (Jacobson et al., 2018). These results are promising, however, 
to better understand the role of the α7 nAChR in developmental ETOH exposure this 
dissertation used compounds that have much higher affinity for this receptor. Because of 
this and the vast amounts of data supporting the receptors role in reducing 
neuroinflammation, excitotoxicity, and behavioral deficits, it could be very useful to 
assess agents that have a higher specificity for the α7 nAChR during critical periods of 
CNS development including during the third trimester brain growth spurt. 
Two Compounds Targeting the α7 nAChR 
 This dissertation investigated the potential of two compounds that target the α7 
nAChR to investigate the importance of this receptor in reducing the deleterious effects 
of developmental ETOH exposure. As stated previously, the damage caused by ETOH 
exposure and EWD is multifaceted and in-turn requires a multi-functional 
pharmacotherapy to treat this damage. Multi-target compounds either hit numerous 
targets simultaneously or are specific to a single target that is capable of interfering with 
several pathological mechanisms. Interestingly, both compounds investigated (discussed 
at length below) appear to reduce excitotoxicity, oxidative stress, and neuroinflammation 
through selective activation of the α7 nAChR. One of the compounds, DMXB-A is 
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derived from marine worms and has gone through several stages of clinical testing for 
various neurological and neurodegenerative diseases (Kem, 2007) but has not been tested 
in developmental ETOH exposure. Though it’s safety has been tested in adults, it would 
clearly need further testing before it could be evaluated in pregnant women and children 
before it could be considered a clinically viable treatment. The flavonoid enriched extract 
Solidago nemoralis on the other hand contains active flavonoids that can be found in 
common crop plants like apples and corn which would classify this compound as a 
“nutraceutical” or “functional food” and make regulatory approval easier to obtain. This 
dissertation aims to compare these two compounds to determine if either Solidago 
nemoralis or DMXB-A is more or less efficacious in reducing behavioral deficits 
following developmental ETOH exposure. Also, neither compound has been investigated 
in our model of ETOH exposure before, and so positive results for either compound 
would further our understanding of the α7 nAChR’s role in reducing developmental 
ETOH exposure as well as potentially lead the way for one or both compounds to be 
investigated clinically to treat developmental ETOH exposure in human populations.  
DMXB-A 
 The first study, discussed in chapter two, investigated 3-dimethoxybenzylidene-
anabasine (DMXB-A) also known as GTS-21 ability to reduce behavioral deficits found 
in our rodent model of developmental ETOH exposure. DMXB-A is a derivative of an 
anabaseine compound found in marine worms (Olincy & Stevens, 2007). It has a high 
affinity for the α7 nAChR, showing about 40% of the efficacy of ACh for the receptor 
and a much lower affinity for other nicotinic receptors like the α4β2 and type 3 5-HT 
receptors where it acts as an antagonist (Kem et al., 2006; de Feibre, 2003; Olincy & 
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Stevens 2007). It is lipophilic and readily crosses lipid membranes such as the blood 
brain barrier (BBB) easily (Kem et al., 2006). In the human brain, DMXB-A is less 
potent than nicotine (Ki=2000) when displacing α-BTX, however in the rat brain DMXB-
A is more potent than nicotine at displacing α-BTX at the α7 nAChR (Ki=650) (Briggs et 
al., 1997). Because the α7 nAChR desensitizes rapidly after activation some researchers 
have considered DMXB-A a partial agonist, however, it is believed that lower 
concentrations of the compound (clinically relevant doses) produce a more prolonged 
effect (for review see Kem et al., 2006, & Li et al., 1999).  In in-vivo animal models 
DMXB-A improved cognitive functioning of eyeblink conditioning in an animal model 
of Alzheimer’s and was neuroprotective against beta-amyloid toxicity (Kem, 2000; 
Kihara et al., 1997; ll et al., 2010; Woodruff et al., 1994). DMXB-A also rescued 
cognitive deficits measured by passive avoidance and spatial working memory after 
mecamylamine exposure in rodents (Meyer et al., 1997). Additionally, it improved object 
recognition and pre-pulse inhibition (PPI) in male rodents who had been given MK-801 
(NMDA receptor antagonist) (Callahan et al., 2014).  DMXB-A was also neuroprotective 
against global ischemia and glutamate-induced excitotoxicity in rodents while also 
improving cognitive function on a passive avoidance task (Nanri et al., 1998). DMXB-A 
has also been suggested to have an anti-inflammatory function by activating the α7 
nAChR and inhibiting LPS-induced TNF- α release from cultured microglia and splenic 
monocytes (Thomsen and Mikkelson, 2012; Yang et al., 2017). Additionally, 
administration of DMXB-A reduced oxidative stress in response to ETOH exposure in  
cells as measured by 2,7-dichlorofluorescin (which detects ROS in cells)(Li et al., 1999). 
Data from in vitro studies suggest that DMXB-A dose-dependently reduced cell death 
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following ETOH exposure in E17 (embryonic) cells, PC12 (pheochromocytoma) cells, 
and in adult male rodents (DMXB-A preexposure 24 h prior to ETOH) (de Fiebre et al., 
2003; Li et al., 2002; Shimohama et al., 1997; Tizabi et al., 2004). As mentioned above, 
the safety of DMXB-A in an adult human population has been verified by its use in 
clinical trials investigating it’s efficacy in the treatment of schizophrenia, Parkinson’s 
disease, and Alzheimer’s disease and more (for review see Freedman et al., 2014 or 
clinicaltrials.gov). In phase II clinical studies of patients with schizophrenia, DMXB-A 
improved attention and memory and sensory inhibition in an animal model of 
schizophrenia (Freedman et al., 2014; Olincy et al., 2007). Taken together, it is apparent 
that DMXB-A can reduce neuroinflammatory response, ETOH-induced neurotoxicity, 
and various behavioral deficits. However, the present study was the first, to the best of 
our knowledge, to explore the ability of DMXB-A to reduce the behavioral deficits of 
third trimester ETOH exposure and withdrawal in male and female rodents.  
Solidago Nemoralis  
 The other compound that was investigated in this dissertation was a flavonoid 
enriched extract called Solidago nemoralis (SN) (derived from the Gray Goldenrod). SN 
was extracted at the University of Kentucky by Naprogenix Inc while exploring various 
plant extracts for their potential α7 nAChR binding properties (Littleton et al., 2005). SN 
had an increased ability to displace methyllycaconitine (MLA, a selective α7 nAChR 
antagonist) in rodent hippocampal cells which demonstrated its specificity for the 
receptor (Lutz, 2014). One important characteristic of SN is its high concentration of 
flavonoids which are highly associated with anti-inflammatory responses in the 
periphery, CNS, and for their neuroprotective effects in models of neurodegeneration 
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(Gonzalez, et al., 2011; Spencer et al., 2012; Dajas et al., 2013). Flavonoids have also 
been studied extensively in models of ETOH exposure. For example, quercetin reversed 
hepatotoxicity and neurotoxicity induced by 90 days of ETOH administration (Ambadath 
et al., 2010). One of the flavonoids found in SN, rhamnetin, demonstrated an ability to 
reduce both neuroinflammation and excitotoxicity in response to EWD in an organotypic 
hippocampal slice culture (Lutz, et al., 2015 b). Goulart and colleagues (2007) also found 
that SN was able to reduce neuroinflammation in the periphery of mice. Though previous 
work with this novel compound is limited, the literature demonstrating that selective 
activation of the α7 nAChR by various flavonoids has the ability to reduce both 
neuroinflammation and excitotoxicity provided a strong rationale for using SN in the 
current study.  
Measuring Efficacy of Pharmacotherapies in Behavioral Animal Models 
For this dissertation, our lab used various tasks to model behaviors that are 
commonly affected in human populations with FAS/FASD. The first task we investigated 
was the open-field, which is an animal test to investigate attention, anxiety, hyperactivity, 
and impulse control through various measures including distance traveled in the 
apparatus (for review see Deneberg, 1969). This test was designed to measure anxiety in 
animals. For rodents, open spaces are aversive because of potential predation and produce 
anxiety-like behaviors including decreased movement, freezing, and maintaining close 
proximity to the walls of the apparatus. Hyperactivity in this task (as measured by 
increased distance traveled) or lack of impulse control (measured by increased entries 
into the center) are believed to be counterintuitive to rodents and indicative of deficits in 
this behavior (Deneberg et al., 1969). As previously mentioned, hyperactivity and deficits 
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in impulse control are common in individuals with FAS/FASD (see Riley et al., 2005). 
These deficits have been also commonly observed using animal models of developmental 
ETOH exposure as well (Jones et al., 2011). In our own lab, we have consistently 
demonstrated increased hyperactivity (as measured by increased distance traveled in the 
open field) in rodents exposed to ETOH during development (see Lewis et al., 2011). 
Thomas and colleagues (2004) demonstrated that perinatal choline supplementation 
reduced hyperactivity in an open-field task in neonatally exposed rodents. This behavior 
is believed to be mediated in part by the basal forebrain and hippocampus because lesions 
of this area have produced increases in activity level (for discussion see Thomas et al., 
2004). These areas are also heavily innervated by nAChR’s, including the α7-nAChR’s 
(Smith et al., 2012; Hurst et al., 2013). So, the hypothesis was that using either of the 
compounds that target the α7-nAChR will be able to reduce hyperactivity produced in our 
model of developmental ETOH exposure. We also used a dowel balance paradigm which 
investigated motor function and coordination. As previously mentioned individuals 
exposed to prenatal ETOH often have motor and coordination deficits (Riley et al. 2011; 
Jones et al., 2011). Various animal models have been developed to investigate similar 
types of motor function as those seen in humans. Dowel rods and roto-rods have been 
commonly used to investigate motor function because they require the animal to maintain 
balance and coordinate movement to be successful in the task (for review see Deacon, 
2013). This task was chosen because previous studies in this lab using this same task, and 
other labs using similar tasks have reliably demonstrated deficits in motor function and 
coordination in rodent models of developmental ETOH exposure (Lewis et al., 2007; 
Thomas et al., 2004 & 2009). Prenatal choline administration after prenatal ETOH 
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exposure was able to decrease deficits in balance and coordination (Thomas et al., 2009). 
In this study, it was believed that this protection against balance deficits was possibly due 
to choline’s effects on the α7-nAChR. This receptor is located in the cerebellum and 
modulates glutamate release within this structure (Hurst et al., 2013; Koukouli & Maskos 
2015). Though this has yet to be explored, it is possible that this modulation of 
glutamatergic receptors in the cerebellum by α7-nAChR during EWD could reduce cell 
death and improve future deficits in balance and coordination. An additional test used to 
investigate the two compounds of interest was a Hebb style water maze developed by 
Von Euler and colleagues (2006). This maze was developed to investigate spatial 
working memory in rodent models. Deficits in spatial working memory, as mentioned 
above, as well as a variety of other deficits regarding memory is very common in both 
FAS and FASD individuals (Jones et al., 2011). These deficits have also been 
characterized in rodent models of developmental ETOH exposure in this lab and others 
(Riley et al., 2005; Lewis et al., 2011; Thomas et al., 2004). The maze we use in our lab 
is a water based spatial navigation task. Much like other spatial navigation tasks (i.e. the 
Morris Maze, the T-Maze, and the Y-maze) our task requires the animal to make a series 
of correct choices over the trial period in order to find the escape platform. One 
advantage to the maze used in the current studies is that the task can be learned in a single 
day and retention of the task can be assessed 24 hours later (see Von Euler et al., 2006 for 
review) in contrast with the more standard “Morris water maze” that’s requires multiple 
days of acquisition and makes interpretation of learning versus retention deficits more 
difficult. This maze is also advantageous relative to other Hebb-like land mazes because 
the animals do not need to be put on a restricted diet in order to complete the task, finding 
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the escape platform is motivated by being in water. As with the previous behaviors, 
several studies have implicated the α7-nAChR in reducing deficits related to spatial 
working memory. First, this task is thought to be largely controlled by the hippocampus 
and prefrontal cortex, both structures that are harmed by developmental ETOH exposure 
(Lebel et al., 2011), and are innervated by the cholinergic system and contains α7-
nAChR’s (Hurst et al., 2013).  Postnatal choline supplementation was able to rescue 
deficits in a spatial navigation task (the Morris Water Maze) after ethanol exposure 
during the third trimester equivalent in rodents (Thomas et al., 2016).  DMXB-A was also 
able to rescue spatial navigation deficits in the Morris task in rodents who had bilateral 
lesions of the nucleus basalis (a structure rich in cholinergic neurons) (Meyer et al., 
1997). Taken together, it appears that as activation of the α7-nAChR can reduce deficits 
in spatial working memory and we hypothesize that our compounds will be able to do the 
same. Finally, in order to test executive function in our animals we used an attentional set 
shifting task (ASST). This task was only assessed in the SN study to determine if future 
use of this paradigm would increase our ability to interpret the efficacy of various 
compounds to reduce behavioral deficits produced by our model of developmental ETOH 
exposure in this and future studies. ASST is considered to be an animal correlate to the 
human Wisconsin card sorting task (see Barnese et al., 2002), where the participant is 
expected to shift between changing rules for reward. In our model, the animal is required 
to shift its attention from odor to odor or media to media, while ignoring the other odor 
and media cues present to receive reward. This task allows assessment of cognitive 
flexibility and reversal learning (a dimension of executive function) which is 
demonstrated in the animals ability to “shift” from a previously rewarded cue to a 
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different cue that is now the target (Waddell & Mooney 2016).  Performance of this task 
appears to be largely controlled by the prefrontal cortex (Birrell & Brown et al., 2000; 
Barnese et al., 2002), a structure that contains many α7-nAChR (Hurst et al., 2013) and is 
particularly sensitive to developmental ETOH exposure (Barron et al., 2017; Goodlett et 
al., 1997; Riley et al., 1993), especially during the third trimester (Ikonomidou et al., 
2000). These deficits are thought to arise from aberrant connectivity from the PFC to 
other structures critical for the performance of set-shifting like the hippocampus (Gorsky 
& Klinstova 2017). Previous studies using a similar task have shown that administration 
of an α7-nAChR agonist can both reduce deficits in an animal model of schizophrenia 
and improve cognitive flexibility in control animals (Wood, et al., 2016). Recently, 
choline supplementation after prenatal ETOH exposure improved deficits in a set-shifting 
task very similar to the task used in the current study (Waddell et al., 2017). Investigating 
this behavior in our model of ETOH exposure is unique in that it has never been done 
before and we hypothesize that our compounds will be able to reduce deficits in this task.  
Project Overview  
This dissertation focuses on the ability of two compounds (DMXB-A and SN) 
that selectively target the α7 nAChR to reduce behavioral deficits associated with 
postnatal “third trimester” ETOH exposure in male and female rodents. The primary 
hypothesis is that one injection of either drug 22 hours after the animal’s final exposure 
to ETOH (during a period of withdrawal) will be able to reduce behavioral deficits 
caused by ETOH exposure. If both drugs successfully rescue behavior after 
developmental ETOH exposure in our model this project will lend support to the theory 
that agonists acting on the nicotinic receptor system, specifically the α7 nAChR, is a 
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promising route to reducing or eliminating ETOH’s adverse effects on developing 
offspring. It will also provide justification to further explore these compounds in other 
models of ETOH exposure and CNS disease/disorder as well as possibly lead to clinical 
development of a pharmacotherapy to treat FAS/FASD.  Both drugs are presented 
separately in their own chapters in a publication-like format.  
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Chapter 2: DMXB-A  
Introduction: 
 Prenatal ethanol (ETOH) exposure can produce a variety of long-term behavioral, 
neuroanatomical and physical deficits. Though prevention would be ideal, the use of 
pharmacotherapies aimed at reducing deficits related to ETOH exposure during fetal 
development is necessary because of the prevalence of ETOH consumption during 
pregnancy (CDC, 2015). In fact, alcohol use among pregnant women in the United States 
was estimated to be at 15% while binge drinking during this same period was around 3% 
(Popova, et al. 2017). The effects of ETOH on the developing nervous system and studies 
aimed at reducing these deficits are numerous (for review see Barron et al., 2017), 
however there is still no medication clinically approved for the treatment of 
developmental ETOH exposure.  
 Previous studies have demonstrated that manipulation of the cholinergic system 
can reduce some of ETOH’s effects on the developing fetus in various animal models of 
developmental ETOH exposure. Within the cholinergic system, activation of central 
nicotinic receptors has shown considerable promise in reducing behavioral deficits 
related to developmental ETOH exposure (Barron et al., 2016, Thomas et al., 2009) as 
well as the ability to reduce alcohol induced cellular toxicity (Hejmadi et al., 2003; 
Shimohama et al., 2001; Prendergast et al., 2000). The alpha 7 nicotinic acetylcholine 
receptors (α7-nAChR) activation is believed to provide neuroprotection from alcohol-
induced neurotoxicity. The receptors high concentration in brain regions associated with 
FAS/FASD’s make it an ideal target (Hurst et al., 2013). Additionally, previous studies 
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have shown that activation of the α7-nAChR reduced alcohol induced cell death in both 
primary neuronal hippocampal cell cultures and PC12 established cell lines (de Fiebre et 
al., 2003, Li et al., 1999). Supplementation with choline, an essential nutrient which has 
high affinity for the α7-nAChR, reduced behavioral deficits after neonatal ETOH 
exposure in rodent models (Ryan et al., 2008, Thomas et al., 2007 & 2009). Though 
treating deficits related to developmental ETOH exposure using compounds like choline 
are promising, it is relatively non-specific and to better understand the role of the α7-
nAChR in this model it is beneficial to use compounds that specifically target this 
receptor. If specific activation of the α7-nAChR’s do reduce deficits produced by 
developmental ETOH exposure it is worth pursuing pharmacotherapies that agonize this 
receptor for treatment of human populations with prenatal ETOH exposure.  
 Of interest to the current project is 3-(2,4-dimethoxybenzylidene)-anabasine 
(DMXB-A) or otherwise known as GTS-21. This compound is promising because of its 
high affinity for the α7-nAChR and the fact that it has been investigated in clinical trials 
for its ability to reduce the cognitive impairing effects of diseases like Alzheimer’s and 
Schizophrenia (Freedman et al., 2014, Kem et al., 2006, Olincy et al., 2007). In-vitro 
studies suggest that DMXB-A can reduce cell death in response to administration of beta-
amyloid in mice (Chen et al., 2010; Kihara et al., 1997), as well as provide 
neuroprotection against global ischemia in rodents (Nanri et al., 1998). When exposed to 
ETOH, DMXB-A dose-dependently reduced excitotoxic cell death in E17 (embryonic) 
cells, PC12 (pheochromocytoma) cells, and in adult male rodents (DMXB-A preexposure 
24 h prior to ETOH), and in rodent organotypic hippocampal cells (de Fiebre et al., 2003; 
Li et al., 1999 & 2002; Shimohama et al., 1997; Tizabi et al., 2004; Fields et al., 
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unpublished). DMXB-A has also been suggested to reduce neuroinflammatory response 
by activating the α7-nAChR and inhibiting LPS-induced TNF- α release from cultured 
microglia and splenic monocytes (Thomsen and Mikkelson, 2012; Yang et al., 2017). 
These actions are promising because both excitotoxicity and neuroinflammation are 
believed to be potent mediators of the damage caused by ETOH exposure which may 
lead to the development of disorders like FAS/FASD (Barron et al., 2017; Crews & 
Nixon, 2009).  In in-vivo animal models DMXB-A improved cognitive functioning 
through eyeblink conditioning in a rodent model of Alzheimer’s (Kihara et al., 1997; 
Chen et al., 2010; Woodruff et al., 1994). DMXB-A was also able to rescue cognitive 
deficits measured by passive avoidance and spatial working memory after mecamylamine 
exposure in rodents (Meyer et al., 1997). It was also able to improve object recognition 
and pre-pulse inhibition (PPI) in male rodents who had been given MK-801 (NMDA 
receptor antagonist) (Callahan et al., 2014). Taken together, it is apparent that DMXB-A 
can reduce neuroinflammatory response, ETOH-induced neurotoxicity, and various 
behavioral deficits. However, the present study was the first, to the best of my 
knowledge, to explore the ability of DMXB-A to reduce the behavioral deficits of third 
trimester ETOH exposure and withdrawal in male and female rodents. We hypothesized 
that DMXB-A would be able to reduce or eliminate the behavioral deficits found after 
“third trimester” ETOH exposure in rodents.    
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Methods: 
Subjects & ETOH Exposure Paradigm: 
 Male and female Sprague Dawley rats were used for all experiments. Offspring 
were bred in the University of Kentucky Psychology Departments breeding facility. Once 
born, half of the offspring were exposed to ETOH (6 g/kg/day) administered by oral 
gavage from postnatal days (PND) 1-7. This model uses a split litter design with 1:1 
male/female ratio designated to each of the following treatment groups: alcohol (6 
g/kg/day), an intubated control, and a non-treated control. All intubated offspring 
received .0278 ml/g of body weight. No more than one male and one female were 
included in any cell of the experimental design to avoid potential litter effects (Abbey & 
Howard, 1973). Intubations were administered in a milk-based diet designed to mimic the 
pups mothers milk (West and Harne, 1984). Two daily feeds were administered at 10AM 
and 2PM and the ETOH exposed offspring received a 3rd intubation at 4PM of milk only 
to account for decreased bodyweight in the ETOH exposed offspring possibly due to 
intoxication or decreased feeding while non-ETOH pups received a sham intubation.  The 
intubation schedule was used to achieve a binge-like pattern of exposure which is 
particularly harmful for the developing fetus (West et al., 1989). Blood ethanol 
concentrations collected previously from this lab have found that BEC’s with this type of 
exposure regime typically peak at 230 mg/dl which returns to 0 within 10 hours after 
intubation (Lewis et al., 2007). These levels of alcohol have been shown to reliably 
produce behavioral deficits in a number of tasks (See Patten et al., 2014) and are 
clinically relevant to the study of developmental ETOH exposure in offspring because 
binge drinkers often display this level of BEC (Cherpitel, 2007). 
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Offspring weight was recorded daily. On PND 8, approximately 21 hours after 
receiving their last intubation, offspring were injected subcutaneously with either a 
vehicle control of 10mg/kg DMXB-A. Previous studies in animal models have found that 
doses from 5-15 mg/kg were efficacious in reducing cell loss and cognitive deficits 
associated with animal models of beta-amyloid toxicity (Callahan et al., 2015; Kem, 
2000; Kihara et al., 1997; ll et al., 2010; Woodruff et al., 1994). This design allowed for 
six treatment groups: milk, milk + drug, ETOH, ETOH + drug, non-treated control 
(NTC), and NTC +drug. The NTC group contained two pups to avoid investigate 
potential intubation effects. At PND 21 the rats were weaned from their mother and 
moved from the nursery room to the colony room of Kastle Hall. 
 All offspring were kept on a 12 hour light/dark cycle, and were allowed 
continuous access to food and water. The care of the offspring was carried out in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (NIH Publications No. 80-23, revised 1996), as well as the 
University of Kentucky’s Institutional Animal Care and Use Committee. 
Drugs: 
For the following experiment DMXB-A was generously provided to the Barron lab by 
Dr. William Kem of the University of Florida. DMXB-A was administered 
subcutaneously on PND 8, 22 hours after the final intubation period. This time was 
chosen because previous research has found that this period of ETOH withdrawal in 
neonates appears to be particularly sensitive to administration of compounds that may 
reduce the excitotoxicity associated with ETOH withdrawal (see Thomas et al., 2006 for 
review). DMXB-A was administered at a dose of 10 mg/kg, a dose that has been 
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previously found to be efficacious in other rodent models of CNS disease/disorder (see 
Li. et al., 2001, & Kem et al., 2006). The drug was suspended in a saline solution and 
offspring that did not receive the drug received an injection of saline alone.  
Behavioral Paradigms: 
Open Field: 
 The Open-Field paradigm was used to investigate rodent hyperactivity and 
impulse control as measured by total distance traveled and distance traveled in the center 
of the apparatus. During open field testing (PND 20-21), offspring were housed with their 
mothers and litter-mates until testing began. On PND 20, pups were taken into the testing 
room alone for 10 min to habituate. The experimental room was illuminated with red 
lights, and a muffin fan which provided white noise. After habituation, each rat was 
placed into a round 55 cm open-field chamber for 30 minutes. The rats' activity was 
recorded using SMART real time video tracking (San Diego Instruments). For analysis, 
the open field was divided into center and outer zones, comprising 25% and 75% of the 
total field area respectively. Total distance traveled, and distance traveled in the center of 
the open field over a 30-minute period was measured. Once testing was completed, 
bodyweights were recorded, and the subjects were returned to their home cage. Both 
chambers were then cleaned with a 30% ETOH solution to eliminate any possible odors 
prior to the next test session.  
Dowel Balance Task: 
This task was chosen because previous studies in this lab using this same task, 
and other labs using similar tasks have reliably demonstrated deficits in motor function 
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and coordination in rodent models of developmental ETOH exposure (Lewis et al., 2007; 
Thomas et al., 2004).  Thomas and colleagues (2009), showed that offspring exposed to 
ETOH and choline on gestational days (5-20) showed similar levels of performance as 
controls on a motor function and coordination task, while ETOH alone offspring 
performed significantly worse. Because of this we hypothesized that DMXB-A would be 
able to reduce deficits in this task produced by our model of developmental ETOH 
exposure.  
On PND 31-33, offspring were tested on a dowel balance paradigm. The 
apparatus consisted of one dowel rod (114cm long, 1.85cm diameter) that was elevated 
(75cm above the ground). Pads were placed under the dowel to avoid injury in case of 
falling. At the end of the dowel there was a black escape box (21x10x17cm). Before 
testing, each rat was handled for three minutes, weighed, and individually housed in the 
colony room. Testing began the following day and continued for three days (PND 31-33). 
The experimental room for the balance task was illuminated with a red light, a muffin fan 
helped reduce extraneous environmental noise during testing. Before testing, each rat was 
brought into the experimental room and habituated to the room for 10 min. On day 1, the 
subject was placed in the escape box for 1 minute to habituate and then returned to their 
home cage for 30 sec. After habituation, the subject was placed on the dowel 10 cm away 
from the escape box and allowed to enter the escape box. Once the subject successfully 
completed a trial, the distance to the goal box was increased by 13cm. A correct trial was 
defined as reaching the escape box without slipping or falling. An incorrect trial was 
defined as a subject slipping (two or more paws falling off the dowel) or falling off the 
dowel completely. Once the animal reached the escape box it was left in the escape box 
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for an additional 10 sec. The subject was then returned to their home cage for 30 sec until 
the next trial began. During the first trial of test days 2 and 3 the animal was placed on 
the dowel 13 cm further than their last successful distance traveled on the previous testing 
day. Total distance traveled on the dowel rod was the dependent measure for this task. 
Once a rat completed the three trials for that day, the dowel was cleaned with 30% ETOH 
before the next subjects were tested. 
Hebb Style Water-Maze 
 This task was chosen because previous studies in this lab using this same task, 
and other labs using similar tasks have reliably demonstrated deficits in spatial navigation 
and working memory in rodent models of developmental ETOH exposure (Lewis et al., 
2011; Thomas et al., 2009; Hunt et al., 2009). Lewis and colleagues demonstrated that 
offspring exposed to ETOH in the same manner as the current study required 
significantly more trials to complete the task on the second day of testing. Also, Thomas 
and colleagues (2004) demonstrated in a similar maze, the Morris Water Maze (a 
paradigm that requires offspring to use spatial navigation and working memory), that 
prenatal ETOH exposure reduced performance compared to controls and concomitant 
choline treatment reduced these deficits. Because of this we hypothesized that DMXB-A 
would be able to reduce deficits in this task produced by our model of developmental 
ETOH exposure. 
 The maze was a 130 x 90 x 40 cm black Plexiglass chamber divided into multiple 
divergent paths, with each path 18 cm wide. The end of the maze was characterized with 
a submerged platform approximately 1cm below the water. The water was mixed with 
non-toxic black powder tempura paint to obscure the platform. The temperature of the 
38 
  
water in the maze was kept at 76 degrees +/-  2 degrees F and temperature of the room 
was 75 degrees +/- 3 degrees F. A plastic sheet surrounded the maze to reduce potential 
external cues from surroundings and the experimenter. The performance of the offspring 
was recorded by the experimenter and SMART real time video tracking software (San 
Diego Instruments). Testing was conducted between PND 40-45 for two days; day 1 was 
termed acquisition day and day 2 was termed retention day. One day prior to testing, each 
rat was handled for 3 min and weighed. On day 1, subjects were habituated to the test 
room for 5 minutes prior to the start of testing. For each trial, the rat was placed at the 
start of the maze. The rat’s swim path was recorded until it reached the platform or after a 
1 minute ceiling had passed (resulting in a failed attempt). If the rat failed to reach the 
platform on a given trial, it was guided to the platform by hand. The rat was allowed to 
stay on the platform for 10 seconds at which time it was removed from the maze and 
placed in a holding cage under a heat lamp until the next trial commenced.  
 This task required thee correct left/right discriminations. A correct trial required 
reaching the platform with no errors.  The learning criterion was defined as two 
consecutive trials with zero errors with a ceiling of 20 trials. At the conclusion of 
acquisition training, the rat was left under the heat lamp for 5min to warm up/dry off and 
then returned to its home cage. The maze was cleaned before the next subject begins 
testing. For day two, the retention period, the same procedure was used as day one.  
Statistical Analysis 
The data were analyzed using SPSS analysis of variance (ANOVA) with either a 
univariate or repeated measure where appropriate. Unless stated otherwise, the milk and 
NTC groups were compared first for similarity; if they showed no significant variation 
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they were then collapsed into a single control group. This was done because the NTC 
group was used to investigate the effect of intubations, if no significant variation was 
found between the two groups it was assumed that intubation itself had no meaningful 
effect and these offspring could be considered control. Variables included sex (2), x 
ETOH (2) x drug (2).  Subsequent ANOVAs were based on the interactions from this 
overall analysis.   If there was no main effect or interaction with sex, the data was 
collapsed across this variable for ease of presentation.  Significant main effects were 
broken down when needed using Least Significant Difference (LSD) post hoc analyses.  
All tests were investigated for outliers and litter effects before statistical analysis, for this 
study no offspring were removed from analysis and there were no significant differences 
between litters regarding performance. Significance for all analyses was set at p<0.05. 
Results: 
Open-Field Performance: 
 Group performance was investigated using total distance traveled for each day 
and distance traveled for each 5-minute time block for each day. The first 5 minutes of 
each day was also investigated as a measure of reactivity to initial placement into the 
chamber. Entries into the center and percentage of time spent in the center of the chamber 
was also investigated because this is a common measure for impulse control (lack of 
inhibition).  
 Our hypothesis was not supported in that males and females exposed to ETOH 
did not demonstrate hyperactivity. Males exposed to ETOH alone and those treated with 
DMXB-A after ETOH exposure had activity levels below that of controls.   
Total Distance Traveled: 
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 A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x day) repeated measure ANOVA 
revealed no significant interactions or main effects between any of the groups. Because of 
an a-priori hypothesis and previous work in this lab, we predicted that ETOH offspring 
would be more hyperactive than control offspring and an LSD post-hoc analysis was used 
to investigate potential group differences. No differences were found between the groups 
for either day. (Fig 2.1.) 
Total Distance Traveled by 5 Minute Time Block: 
A 2 x 2 x 2 x 2(6) (Sex x ETOH x DMXB-A x Day[5-minute block]) repeated 
measures ANOVA revealed that there was a significant main effect of Sex x ETOH x Day 
(5-minute, F(1,76)=3.378, p<.05). Because of this interaction involving sex, males and 
females were investigated separately for these analyses.  For males, an overall repeated 
measures analysis (ETOH x DMXB-A x block [2 x 2 x 2{6}]) revealed there was not a 
significant interaction between group and time block or a main effect of group on days 
one or two. Because of an a-priori hypothesis and previous work in this lab, however, we 
predicted that ETOH offspring would be more hyperactive than control offspring for both 
sexes.  Analysis revealed that in males, both ETOH and ETOH + DMXB-A groups were 
significantly less active (p<.05) than control offspring in the first five minutes of day one. 
A similar difference between control offspring and ETOH + DMXB offspring occurred 
during the first five minutes of day two (see Fig. 2.2 & 2.4). For females, no group 
significantly differed from control animal performance for any time point on either day 
(see Fig. 2.3 & 2.5).  
Total Distance Traveled in the Center: 
 Again, our hypothesis was not supported, in that offspring exposed to ethanol and 
41 
  
treated with DMXB-A were more active in the center than control offspring during day 2 
testing, an effect not seen in offspring exposed to only ETOH. 
 A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x day) repeated measure ANOVA 
revealed that there was a significant interaction between ETOH and DMXB-A, 
F(1,76)=5.413, p<.05.  LSD post-hoc analysis revealed on day two, offspring exposed to 
ETOH and treated with DMXB-A traveled significantly more distance than offspring 
treated with ETOH (p<.05), however, neither of these groups differed significantly from 
control offspring. (see Fig. 2.6) 
Total Distance Traveled in the Center by 5 Minute Time Block: 
 A 2 x 2 x 2 x 2(6) (Sex x ETOH x DMXB-A x Day[5-minute block]) repeated 
measures ANOVA revealed that there was a significant interaction between ETOH and 
DMXB-A, F(1,76)=5.420, p<.05. However, an LSD post-hoc analysis revealed that there 
were no significant group differences on either day. However, on day two during the first 
five minutes the offspring exposed to ETOH and treated with DMXB-A demonstrated a 
trend toward increased activity that was approaching significant difference from controls. 
(see Fig. 2.7 and 2.8) 
Entries into the Center: 
 A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x Day) repeated measures ANOVA 
revealed that there were no significant interactions or main effects for entries into the 
center of the apparatus. An LSD post-hoc test investigating individual group differences 
also revealed no significant difference between any of the group for either day.  (Fig . 2.9) 
Percentage of time spent in the center: 
 A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x Day) repeated measures ANOVA 
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revealed that there was a significant interaction between ETOH and DMXB-A for 
percentage of time spent in the center, F(1,76)=6.041,p<.05. An LSD post-hoc analysis 
revealed that on day two, offspring exposed to ETOH and treated with DMXB-A spent 
more time (p<.05) in the center of the apparatus than control offspring. (Fig. 2.10)   
Balance Performance:  
 Our hypothesis was supported in female offspring because those treated with 
ETOH performed significantly poorer than control females on the dowel task. Treatment 
with DMXB-A in ETOH exposed females reduced this deficit to control levels. This 
effect was not observed in male offspring, instead, treatment with DMXB-A in ETOH 
exposed males decreased performance on this task. Results presented below.  
 A 2 x 2 x 2 x 3(3) repeated measures ANOVA (sex x ETOH x DMXB x day 
[trial]) was conducted and yielded an interaction between sex and DMXB 
F(1,109)=6.007,p<.05. Because of this, further analyses were broken down by sex and 
investigated separately. A 2 x 2 x 3(3) (ETOH x DMXB x Day[Trial]) repeated measures 
analysis in males revealed a main effect of DMXB F(1,48)=4.152, p<.05. After 
investigating group differences using a post-hoc analysis, it was revealed that ETOH 
males treated with DMXB achieved significantly less distance on the dowel (p<.05) than 
control offspring during trial 3 of day 2, and trial 1 & 2 of day 3 (see Fig. 2.11 & 2.12). 
This difference however was not significant in the final trial of testing. For females, there 
was a main effect of ETOH, F(1,61)=5.036, p<.05. A post-hoc analysis revealed that 
during the final trial of testing (day 3 trial 3) that ETOH females traveled significantly 
less distance on the dowel (p<.05) than control females. This difference was not observed 
in any of the other groups in female offspring (see Fig. 2.13 & 2.14).  
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Water Maze Performance: 
 Our hypothesis was again supported in the water-maze task, males treated with 
DMXB-A after ETOH exposure performed at control levels during acquisition where 
males exposed to ETOH required more trials to reach criterion. This effect was not 
observed in females; however, DMXB-A treatment did reduce the amount of trials 
required to reach criterion to below that of control females during task retention. 
 A 2 x 2 x 2 x 2 (sex x ETOH x DMXB x day) repeated measures ANOVA 
revealed that there was a sex x ETOH interaction F(1,94)=4.884, p<.05, and a main effect 
of ETOH F(1,94)=6.288, p<.05. Because of this each sex was investigated separately. In 
males, a 2 x 2 x 2 (ETOH x DMXB x day) analysis revealed a main effect of ETOH 
F(1,38)=14.249, p=.001, but no interaction or main effect of DMXB. LSD post-hoc 
analysis revealed that during acquisition ETOH exposed males required significantly 
more (p=.001) trials to reach criterion than did control offspring during acquisition and 
ETOH exposed males treated with DMXB-A performed at control levels (see Fig. 2.15). 
In females, the initial 2 x 2 x 2 analysis revealed no interactions or main effects of ETOH 
or DMXB. However, due to the a-prior hypothesis that treatment groups would differ an 
LSD post-hoc analysis revealed that during retention females treated with DMXB 
required significantly less (p<.05) trials to reach criterion than control offspring did (see 
Fig. 2.16).  
Body Weights: 
For all tasks, body weight was recorded after testing. For open-field, weights were 
recorded on PND 21 and analyzed with neonatal treatment and sex as grouping variables 
(see Table 2.1). As predicted, a 2 x 4 ANOVA revealed a main effect of both sex 
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F(1,76)=5.903, p<.01, where males reliably weighed more than females, and treatment 
group F(1,76)=4.780, p<.01 but no interaction. Post-hoc analysis revealed that offspring 
treated with ETOH weighed less than control offspring (p<.05), an effect which was not 
present in the ETOH offspring treated with DMXB-A. For balance, the ANOVA revealed 
a main effect of sex F(1,101)=28.906, p<.001 and ETOH F(1,101)=4.105, p<.05, where 
males consistently weighed more than females. Females exposed to ETOH weighed less 
than control females. This difference was not significant in males. For water maze, the 
analysis revealed a main effect of sex F(1,86)=112.495, p<.001 and a main effect of 
group F(1,86)=3.305, p<.05, and no interaction. Males, as predicted, were reliably 
heavier than their female counterparts in all groups, and males treated with ETOH were 
significantly lighter than any of the offspring from the other remaining groups. 
Discussion: 
 This study was designed to examine whether DMXB-A (at a dose of 10mg/kg) 
could reduce the behavioral deficits produced by developmental ETOH exposure during 
the 3rd trimester brain growth spurt in rodents. In short, DMXB-A appeared to reduce 
some of the deficits produced by developmental ETOH exposure associated with motor 
coordination in female offspring and memory and spatial navigation in males. However, 
several of the findings were unexpected and demonstrated that DMXB-A’s effects 
appeared to be sex dependent and that the combination of DMXB-A and ETOH may be 
deleterious to certain behaviors. 
 Previous research in this lab and others has demonstrated that developmental 
ETOH exposure, particularly during the third trimester, can impair behaviors related to 
attention/hyperactivity (Smith et al., 2012; Thomas et al., 2007; Lewis et al., 2012), 
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learning/memory (Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012), and 
coordination/balance (Idrus et al., 2011; Lewis et al., 2007; Thomas et al., 2004).  It is 
believed that these behaviors are compromised because the structures that mediate these 
behaviors including the cerebellum, hippocampus, and prefrontal cortex are undergoing 
great growth and development during the third trimester and are more sensitive to 
ETOH’s teratogenic effects (for review see Dobbing & Sands, 1979; Riley & McGee, 
2005 & Patten et al., 2014).  
The first behavior investigated was activity as measured in an open-field chamber. 
As mentioned previously, this task was used in the current study because like humans, 
rodents who are exposed to ETOH during development demonstrate hyperactivity (for 
review see Mattson et al., 2011 & Patten et al., 2014). Activity is typically assessed by 
several measures including path length, entries into, or time spent in specific areas of the 
chamber; normal rodent activity is typically increased in the beginning of a trial, 
reflecting investigation of novel surroundings, while also avoiding the center or open 
areas of the chamber, avoiding potential predation (for review see Denenberg, 1969). In 
offspring who were exposed to ethanol during critical developmental periods, like the 
third trimester, activity in the open-field is typically increased (hyperactivity as expressed 
in greater total path length), and greater exploration of the center of the open-field (as 
measured by path length in the center or number of entries into the center) is common 
which is characterized as hyperactivity and lack of inhibition (Schneider et al., 2011). 
These deficits are associated with regions of the brain including the prefrontal cortex 
(Gorsky & Klinstova 2017) and the basal ganglia (Thomas et al., 2004) that are 
particularly sensitive to third trimester ETOH exposure (Riley et al., 2011). These 
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structures are also innervated by the cholinergic system and contain α7-nAChR ‘s (Hurst 
et al., 2013). Though investigation of compounds that directly activate the α7-nAChR’s 
effects of this behavior in developmental ETOH exposure models have not been 
previously investigated, it is believed that activation of this receptor, through choline 
supplementation, can reduce deficits in this task (Thomas et al., 2004 & 2009).  In the 
current study neither male nor female offspring exposed to ETOH displayed increased 
activity in the current study. Previous studies in this lab using the same model of ETOH 
exposure and task for assessing activity levels have reliably found increased activity in 
offspring exposed to ETOH both in overall activity, activity in the center, and entries into 
the center (Lewis et al., 2011, Smith et al., 2012). It is unclear why performance in this 
paradigm would be any different from performance in previous studies. It becomes even 
more perplexing when an effect of ETOH was found in our other tasks (see balance and 
water maze below). When considering possible explanations one path would be 
comparing activity levels in this study to previous studies conducted in this lab. For this, 
average activity in control offspring was compared between this study and the Smith et 
al., (2012) study; average activity was approximately the same as the current study 
(around 2000 cm. total distance traveled for both days). Interestingly, they did not find an 
effect of ETOH on total distance traveled for day 2 in respect to control performance, but 
ETOH did increase entries into the center of the apparatus for both days. The current 
study did not find an effect of ETOH in either distance traveled for either day or entries 
into the center. Additionally, neither Smith and colleagues (2012) or Lewis and 
colleagues (2011) found any differences between male and female offspring in activity in 
response to developmental ETOH exposure. Investigations into the BAC’s for this model, 
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though not conducted in the current study, demonstrated that this model produces BAC’s 
up to 220 mg/dl 60 minutes after intubation (Lewis et al., 20011). As mentioned 
previously, BAC’s in this range have reliably found deficits in the behaviors investigated 
for this study (see Painter et al., 2014 for review). Additionally, males exposed to 
DMXB-A and ethanol had reduced activity when compared to control offspring for the 
beginning of day 1 and day 2 testing. Also, center activity (distance traveled and time 
spent) was increased during day 2 above control levels when ETOH was combined with 
DMXB-A, but not in offspring exposed to ETOH alone. Though previous studies have 
not been conducted investigating DMXB-A’s effects on activity level after third trimester 
ETOH exposure, or any model of developmental ETOH exposure, we expected the 
combination of DMXB-A and ETOH to have similar performance to that of control 
animals. Previous studies investigating DMXB-A’s side-effect profile compared to 
nicotine found that DMXB-A had no effect on activity levels in healthy mice or rats 
while nicotine alone increased activity levels, which was reflected in the current study 
(Nanri et al., 2001). It is possible that the combination of ETOH and DMXB-A in the 
current model produces some type of sedation, however, other studies using α-7 nAChR 
activating compounds like choline, found that after exposing male rodents to ethanol 
during PND’s 4-9, choline supplementation was able to reduce increased activity levels 
produced by ETOH exposure to control levels (Thomas et al., 2004). Similar findings 
were observed with prenatal ethanol exposure in male and female rodents, where ethanol 
exposed rodents had significantly increased activity compared to controls and prenatal 
supplementation with choline was able to reduce these deficits (Thomas et al., 2009). 
However, the studies investigating these compounds effects on developmental ETOH 
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exposure reliably found an effect of ETOH administration both in pre and postnatal 
models. Because of this, it becomes difficult to compare the results of DMXB-A in this 
test with other studies using compounds that target the α-7 nAChR.    Future 
investigations in this lab using this exposure model with the open-field task should be 
completed to determine a possible cause for this difference because the use of this task is 
invaluable in determining the efficacy of compounds aimed at reducing the effects of 
developmental ETOH exposure.  
 DMXB-A was also investigated for its ability to reduce deficits in motor 
coordination after developmental ETOH exposure. This paradigm was used because 
deficits in motor function and coordination (as measured by distance traveled in the 
current study) are common in both clinical cases and animal models of FAS/FASD (Idrus 
et al., 2011; Lewis et al., 2007; Thomas et al., 2004). As previously mentioned, this task 
is believed to be largely mediated by the cerebellum, a structure that is sensitive to the 
effects of developmental ETOH exposure, particularly during the third trimester brain 
growth spurt (see Riley & McGee, 2005 for review). Additionally, the cerebellum is 
innervated by the cholinergic system and contains α7-nAChR (Hurst et al., 2013). In the 
current study, our hypothesis that developmental ETOH exposure would decrease 
distance achieved and a single injection of DMXB-A would reduce these deficits to 
control levels was supported, but only in female animals. However, our hypothesis was 
not supported in males where ETOH exposure alone had no effect and distance achieved 
was significantly decreased below that of controls after treatment with DMXB-A in 
ethanol exposed offspring. Previous research using the same model of ETOH exposure 
and methods for investigating motor function as the current study have typically found 
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coordination deficits in both male and female offspring exposed to ETOH (Lewis et al., 
2007 & 2011). Interestingly, in one of these studies they observed sex differences in 
motor function, however, these differences were in untreated offspring where females 
performed better than males overall, with no effect on those treated with ETOH or ETOH 
+ Drug (Lewis et al., 2007). They posited that these differences in sex occurred because 
of the weight discrepancies between males and females, where females generally weigh 
less than males and thus stand to do better on the dowel rod. Interestingly, we did not see 
this effect in the current study, even though males weighed significantly more than 
females, they performed at roughly equivalent levels (around 600 +/- cm total). Males 
exposed to ETOH and ETOH and DMXB-A also did not differ from controls regarding 
weight. Decreased performance on this task in males exposed to ETOH and treated with 
DMXB-A has not been supported by previous literature. Though DMXB-A has not yet 
been investigated for its ability to reduce motor deficits in developmental ETOH 
exposure; studies testing the ability of α7-nAChR activating compounds to reduce these 
deficits have not shown a reduction in performance when combined with ETOH exposure 
in either sex (Thomas et al., 2004 & 2016). In fact the results mirror what was 
demonstrated in the female’s performance (Thomas et al., 2004 & 2016). It is promising 
that DMXB-A was able to reduce the deficit found in females exposed to ethanol on this 
balance task, however, it is obvious that further work needs to be completed to explore 
the potential effects of ETOH exposure on task performance in male and female 
offspring.  
 Finally, DMXB-A was investigated for its ability to reduce learning and memory 
deficits in a Hebb style water maze after developmental ETOH exposure. As mentioned 
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previously, this paradigm was chosen because it demonstrates both learning (during maze 
acquisition) and memory (during maze retention) in only two days (for review see Von 
Euler et al., 2006). This task is also useful because it tests a behavior (learning/memory) 
that is commonly deficient in both clinical cases and animals models of FAS/FASD’s 
(Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012). The task is believed to use 
both spatial navigation and working memory which is thought to be largely mediated by 
the hippocampus and prefrontal cortex (Von Euler et al., 2006), structures that are 
sensitive to the teratogenic effects of developmental ETOH exposure, particularly during 
the third trimester (see Riley & McGee, 2005 for review). These structures are also 
innervated by the cholinergic system and contain α7-nAChR’s (Hurst et al., 2012).  In 
support of the hypothesis, ethanol exposure increased the total amount of trials required 
to reach criterion in males and a single injection of DMXB-A reduced this deficit to 
control levels during maze acquisition. This effect was not observed in females. 
Interestingly, during retention, there were no significant differences between any of the 
groups in males, but in females those offspring treated with DMXB-A alone required 
significantly fewer trials than their respective controls to complete the task. The sex 
differences observed in the current study in response to ETOH have not been found 
previously using this model or task. Studies in this lab using the same methodology and 
exposure model did not find sex differences in this task, and the offspring exposed to 
ETOH had retention deficits and not acquisition deficits like in the present study (Lewis, 
et al., 2011). Interestingly, Goodlett & Peterson (1995) suggested females performance 
on spatial navigation tasks may be less sensitive to ETOH exposure than males which we 
did observe. In regards to the acquisition deficit, it is possible that these results stem from 
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ETOH’s effects on the hippocampus, the structure thought predominately responsible for 
spatial navigation tasks, where early maze learning seems to rely on the hippocampus 
proper but retention may be mediated more by the striatum (for review see Berman & 
Hannigan, 2000). However, research shows that both the striatum and hippocampus are 
sensitive to developmental ETOH exposure (Fryer et al., 2007). As for DMXB-A’s 
ability to increase performance in retention in females compared to control; it is possible 
that activation of the α7-nAChR could increase cognition. In fact, previous studies have 
supported this claim; where activation of the receptor by choline supplementation 
improved executive functioning and learning and memory in control offspring (Thomas 
et al., 2000). However, this effect was seen in both males and females in the Thomas 
study and was only demonstrated in female offspring in the current study. Though not sex 
specific, other studies investigating DMXB-A in an animal model Alzheimer’s model 
have demonstrated that it can increase cognitive deficits in other hippocampal including 
eyeblink conditioning (Kihara et al., 1997; Chen et al., 2010). Again, further work is 
necessary to elucidate the differences between acquisition and retention in response to 
developmental ETOH exposure, activation of the α7-nAChR, and the possible effect sex 
has on those behaviors.   
 These results are the first to report on DMXB-A’s effects on behavior in a third 
trimester developmental ETOH exposure model. The results demonstrate the potential of 
DMXB-A to reduce some of the behavioral deficits associated with developmental 
ETOH exposure. However, there were several unexpected results and it is possible that 
the combination of DMXB-A and ETOH could be detrimental to certain behaviors. As 
previously mentioned, targeting EWD, a process that is severely damaging to the 
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developing nervous system (Riley et al., 2011) is one potential avenue for reducing 
deficits related to FAS/FASD and could be a one-time treatment. The mechanism for the 
damage caused by EWD, as reviewed above, is thought to be predominately produced by 
excitotoxicity, oxidative stress, and neuroinflammation (Alfonso-Loeches et al., 2011). 
DMXB-A, a compound that has shown affinity for binding at the alpha7 receptor has 
been shown to reduce these types of damage in cellular models of ETOH exposure (de 
Fiebre et al., 2003; Li et al., 2002; Shimohama et al., 1997; Tizabi et al., 2004). This is 
promising because as mentioned previously, there are currently no pharmacotherapies 
clinically approved to treat FAS/FASD.  Clearly more work is necessary with DMXB-A 
to further elucidate the differences in our behavioral studies as well as to further 
understand its actions in the nervous system. However, the clinical utility of compounds 
that target the α7-nAChR seem clear, and because there are currently no clinically 
approved medications for the treatment of FAS/FASD further work must be done to 
explore this compound and other compounds that target this system.  
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Tables: 
 
  
Table 2.1: DMXB-A Study Animal Weights  
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Figure. 2.1: Open-Field performance as measured by total distance traveled. None of the 
groups differed in total distance traveled for either day  
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Figure. 2.2: Male Open-Field performance as measured by distance traveled. On day 1, 
ETOH & ETOH+DMXB-A offspring traveled significantly less distance than control offspring in 
the first 5 minutes of the trial. A similar pattern was seen on day two where ETOH+DMXB-A 
offspring traveled significantly less distance than control offspring. These differences 
dissipated as the trial continued.  *p<.05, differs significantly from control offspring.  
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Figure. 2.3: Female Open-Field performance as measured by distance traveled. On day one 
and day two there no significant differences between any of the groups. 
57 
  
 
 
Figure. 2.4: Male Open-Field performance as measured by distance traveled in the first five 
minutes. On day 1, ETOH & ETOH+DMXB-A offspring traveled significantly less distance than 
control offspring in the first 5 minutes of the trial. A similar pattern was seen on day two 
where ETOH+DMXB-A offspring traveled significantly less distance than control offspring. 
These differences dissipated as the trial continued.  *p<.05, differs significantly from control 
offspring. 
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Figure. 2.5: Female Open-Field performance as measured by distance traveled in the first 
five minutes. There were no significant group differences between the groups on either day. 
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Figure. 2.6: Open-Field performance as measured by distance traveled in the center of the 
apparatus. On day 1, there were no significant difference between groups. However, on day 
two those offspring exposed to ethanol and treated with DMXB-A traveled significantly 
more distance than those offspring exposed to ETOH alone. Neither group differed from 
controls.  += p<.05, differs significantly from ETOH offspring. 
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Figure. 2.7: Open-Field performance as measured by distance traveled in the center of the 
apparatus. There were no significant group differences between the groups on either day. 
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Figure. 2.8: Open-Field performance as measured by distance traveled in the center of the 
apparatus for the first 5 minutes of testing. There were no significant group differences 
between the groups on either day. 
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Figure. 2.9: Entries into the center of the open-field chamber. There were no significant 
group differences for either day.  
63 
  
 
 
Figure. 2.10: Time spent in the center (%) of the open-field chamber. There were no 
significant group differences for day 1. However, offspring exposed to ETOH and treated 
with DMXB-A had an increased amount of time spent in the center compared to control 
offspring. *p<.05 from control 
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Figure. 2.11: Male Balance performance as measured by distance traveled. Ethanol exposed 
males treated with DMXB traveled significantly less distance than control males for three 
trials, however this difference was not present during any other trial. *p<.05, differs 
significantly from control offspring. 
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Figure. 2.12: Male Balance performance as measured by distance traveled. There were no 
significant differences in total distance traveled between any of the groups.  
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Figure. 2.13: Female Balance performance as measured by distance traveled. The pattern of 
reduction in performance in ETOH exposed offspring was consistent throughout testing, 
however this difference was significant during the last trial of testing. *p<.05, differs 
significantly from control offspring. 
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Figure. 2.14: Female Balance performance as measured by distance traveled. Ethanol 
exposed females traveled significantly less distance than control females. A single injection 
of DMXB-A reduces this deficit to control levels.  *p<.05, differs significantly from control 
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Figure. 2.15: Male water maze performance as measured by trials to completion. ETOH 
males required significantly more trials than control males during acquisition to reach 
criterion and the addition of DMXB-A to ethanol exposed offspring reduced this deficit to 
control levels. *p=.001, differs significantly from control offspring. 
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Figure. 2.16: Female water maze performance as measured by trials to completion. Females 
treated with DMXB required significantly less trials than control females during retention to 
reach criterion. *p<.05, differs significantly from control offspring. 
70 
  
Chapter 3: Solidago Nemoralis  
Introduction: 
Alcohol is one of the most commonly used drugs in the western world, with an 
estimated 87% of individuals (18 years of age or older) reporting that they had consumed 
alcohol at some point in their lifetime, 70% in the last year, and 56 % in the last month 
(NIAAA, 2015). In addition, approximately 10% of pregnant women consume alcohol at 
some point during pregnancy with a third of these women binge drinking (Center for 
Disease Control (CDC), 2015). Prenatal ethanol (ETOH) exposure has serious 
consequences for the developing offspring which at times manifests as Fetal Alcohol 
Syndrome/ Spectrum Disorders (FAS/FASD) (Hoyme, et al. 2005). Estimates of the 
prevalence of these disorders has been conservatively estimated to be 1-5% in first grade 
children, with a cost of approximately $4 billion annually in the United States (CDC, 
2015; May et al., 2018). 
Exposure to ETOH during development can sometimes lead to a multitude of both 
behavioral and physiological problems throughout the offspring’s lifetime (for review see 
Riley et al., 2011). Such behavioral impairments include issues with executive 
functioning, motor coordination, spatial learning, attention, and hyperactivity (Jones, 
2011; Mattson & Riley, 1998). Because of this, considerable amounts of research have 
been focused on treating these disorders, however no medications aimed at treating 
FAS/FASD specifically have been clinically approved. Of the many possible targets for 
treatment currently being investigated, treating ETOH withdrawal (EWD) in the neonate 
has proven to be a promising path for possibly negating the effects of developmental 
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ETOH exposure. Previous work has shown that EWD is a potential mediator in much of 
the damage in the central nervous system (CNS) that inevitably leads to many of these 
deficits (Barron et al., 2008; Goodlett & Horn 2001; Thomas et al., 1997). This damage 
caused by EWD is thought to be facilitated, in part, by excitotoxicity, neuroinflammation, 
and oxidative stress (Lutz et al., 2015; Barron et al., 2017; Crews & Nixon, 2009). 
Targeting these forms of toxicity associated with EWD is promising because it could 
potentially be a one-time treatment that would protect the fetus or newborn during a time 
when ETOH is absent from the system. This treatment could either be administered 
during parturition, or when a mother is seeking help for an alcohol use disorder. 
The cholinergic system, a system that is critical in mediating behaviors related to 
wakefulness and attention, as well as learning and memory, has shown considerable 
promise in reducing some of the effects of developmental ETOH exposure on the fetus 
and newborn in various animal models (Barron et al., 2016, Thomas et al., 2003, 2004 & 
2009).  Activation of receptor subsystems within the cholinergic system, particularly 
those found in the CNS, have been useful in their ability to reduce various excitotoxic 
challenges. Activation of the nicotinic system can increase cell survival after hypoxic 
events, ETOH withdrawal and beta-amyloid-mediated cell death in cortical cultures 
(Hejmadi et al., 2003; Shimohama et al., 2001; Prendergast et al., 2000), and also reduce 
NMDA induced excitotoxicity in the hippocampus after chronic nicotine administration 
(Ferchmin et al., 2003; Prendergast et al., 2001). Within the nicotinic system, the alpha 7 
nicotinic acetylcholine receptor (α7-nAChR), a calcium permeable ion channel, is 
particularly interesting because of its high concentration in regions of the CNS associated 
with FAS/FASD’s, including the hippocampus, frontal cortex, and cerebellum (Hurst et 
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al., 2013). The receptor is also commonly found on neuroimmune cells that mediate 
neuroinflammatory responses (Xiu et al., 2005). Activation of the α7-nAChR has also 
been shown to reduce cellular toxicity during ethanol withdrawal (de Fiebre et al., 2003 
& 2005; Yangxin et al., 2002). Supplementation with choline, an essential nutrient, which 
has a high affinity for the α7-nAChR, has shown considerable promise in reducing 
deficits related to fetal ETOH exposure in rodents (Thomas, 2009). Choline 
supplementation has been shown to reduce hyperactivity, spatial working memory 
deficits, eye-blink and trace fear conditioning, and executive functioning deficits 
following developmental ETOH exposure (Monk, 2012; Waddell & Mooney, 2017). 
Thomas and colleagues (2009) reported that choline supplementation during early 
development increased birth and brain weight after ETOH exposure. Interestingly, a 
recent study using choline supplementation in pregnant women who had consumed 
alcohol reduced the amount of adverse effects caused by prenatal ETOH exposure (low 
birth weight, and cognitive deficits) compared to women given a placebo (Jacobson et al., 
2018). Though treating deficits related to developmental ETOH exposure using 
compounds like choline are promising, it is relatively non-specific and to better 
understand the role of the α7-nAChR in this model it is beneficial to use compounds that 
specifically target this receptor. If an agonist of the α7-nAChR’s can reduce deficits 
produced by developmental ETOH exposure it is worth pursuing pharmacotherapies that 
agonize this receptor for treatment of human populations with prenatal ETOH exposure.  
Solidago nemoralis (SN) is a flavonoid enriched extract derived from the Gray 
Goldenrod. SN was extracted at the University of Kentucky by Naprogenix Inc while 
exploring various plant extracts for their potential α7-nAChR binding properties 
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(Littleton et al., 2005). SN demonstrated an increased ability to displace MLA (a selective 
α7-nAChR antagonist) in rodent hippocampal cells which demonstrated its specificity for 
the receptor (Lutz, 2014). One important characteristic of SN is its high concentration of 
flavonoids which are highly associated with anti-inflammatory responses in the 
periphery, CNS, and for their neuroprotective effects in models of neurodegeneration 
(Gonzalez, et al., 2011; Spencer et al., 2012; Dajas et al., 2013). Flavonoids have also 
been studied extensively in models of ETOH exposure as well. For example, quercetin 
reversed hepatotoxicity and neurotoxicity induced by 90 days of ETOH administration 
(Ambadath et al., 2010). One of the flavonoids found in SN, rhamnetin, demonstrated an 
ability to reduce both neuroinflammation and excitotoxicity in response to EWD in an 
organotypic hippocampal slice culture (Lutz, et al., 2015 b). Goulart and colleagues 
(2007) also found that SN was able to reduce neuroinflammation in mouse model of 
pleurisy. Though previous work with this novel compound is limited, the amount of 
literature demonstrating that selective activation of the α7-nAChR has the ability to 
reduce both neuroinflammation and excitotoxicity provided a strong rationale for using 
SN in the current study. We hypothesized that SN would be able to reduce or eliminate 
the behavioral deficits found after “third trimester” ETOH exposure in rodents.    
Methods: 
Subjects & ETOH Exposure Paradigm: 
 Male and female Sprague Dawley rats were used for all experiments. Offspring 
were bred in the University of Kentucky Psychology Departments breeding facility. Once 
born, half of the offspring were exposed to ETOH (6 g/kg/day) administered by oral 
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gavage from postnatal days (PND) 1-7. This model uses a split litter design with 1:1 
male/female ratio designated to each of the following treatment groups: alcohol (6 
g/kg/day), an intubated control, and a non-treated control. All intubated offspring 
received .0278 ml/g of body weight. No more than one male and one female were 
included in any cell of the experimental design to avoid potential litter effects (Abbey & 
Howard, 1973). Intubations were administered in a milk-based diet designed to mimic the 
pups mothers milk (West and Harne, 1984). Two daily feeds were administered at 10AM 
and 2PM and the ETOH exposed offspring received a 3rd intubation at 4PM of milk only 
to account for decreased bodyweight in the ETOH exposed offspring possibly due to 
intoxication or decreased feeding while non-ETOH pups received a sham intubation.  The 
intubation schedule was used to achieve a binge-like pattern of exposure which is 
particularly harmful for the developing fetus (West et al., 1989). Blood ethanol 
concentrations collected previously from this lab have found that BEC’s with this type of 
exposure regime typically peak at 230 mg/dl which returns to 0 within 10 hours after 
intubation (Lewis et al., 2007). These levels of alcohol have been shown to reliably 
produce behavioral deficits in a number of tasks (See Patten et al., 2014) and are 
clinically relevant to the study of developmental ETOH exposure in offspring because 
binge drinkers often display this level of BEC (Cherpitel, 2007). 
Offspring weight was recorded daily. On PND 8, approximately 21 hours after 
receiving their last intubation, offspring were injected subcutaneously with either a 
vehicle control of 50mg/kg SN. This design allowed for six treatment groups: milk, milk 
+ drug, ETOH, ETOH + drug, non-treated control (NTC), and NTC +drug. The NTC 
group contained two pups to avoid investigate potential intubation effects. At PND 21 the 
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rats were weaned from their mother and moved from the nursery room to the colony 
room of Kastle Hall. 
 All offspring were kept on a 12 hour light/dark cycle, and were allowed 
continuous access to food and water. The care of the offspring was carried out in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (NIH Publications No. 80-23, revised 1996), as well as the 
University of Kentucky’s Institutional Animal Care and Use Committee. 
Drugs: 
For the following experiment SN was generously provided to the Barron lab by 
Dr. John Littleton of the University of Kentucky. SN was administered subcutaneously on 
PND 8, 21 hours after the final intubation period. This time was chosen because previous 
research has found that this period of ETOH withdrawal in neonates appears to be 
particularly sensitive to administration of compounds that may reduce the excitotoxicity 
associated with ETOH withdrawal (see Thomas et al., 2006 for review). SN was 
administered acutely at a dose of 50 mg/kg, a dose previously found efficacious in 
reducing inflammation in a mouse model of pleurisy (Goulart et al., 2007). The drug was 
suspended in a saline solution and offspring not receiving the drug received an injection 
of saline alone.  
Behavioral Paradigms: 
Open Field: 
 The Open-Field paradigm was used to investigate rodent hyperactivity and 
impulse control as measured by total distance traveled and distance traveled in the center 
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of the apparatus. As previously mentioned, hyperactivity and deficits in impulse control 
are common in individuals with FAS/FASD (see Riley et al., 2005). These deficits have 
been observed using animal models of developmental ETOH exposure as well (Mattson 
et al., 2011). Thomas and colleagues (2004) demonstrated that perinatal choline 
supplementation reduced hyperactivity in neonatally exposed rodents. Because of this, we 
hypothesize that SN will reduce hyperactivity in our model of developmental ETOH 
exposure. 
During open field testing (PND 20-21), offspring were housed with their mothers 
and litter-mates until testing began. On PND 20, pups were taken into the testing room 
alone for 10 min to habituate. The experimental room was illuminated with red lights, 
and a muffin fan which provided white noise. After habituation, each rat was placed into 
a round 55 cm open-field chamber for 30 minutes. The rats' activity was recorded using 
SMART real time video tracking (San Diego Instruments). For analysis, the open field 
was divided into center and outer zones, comprising 25% and 75% of the total field area 
respectively. Total distance traveled, and distance traveled in the center of the open field 
over a 30-minute period was measured. Total activity and activity in the center is 
considered a potential marker for impulsivity and/or anxiety (for review see Royce, 
1977). Once testing was completed, bodyweights were recorded, and the subjects were 
returned to their home cage. Both chambers were then cleaned with a 30% ETOH 
solution to eliminate any possible odors prior to the next test session.  
Dowel Balance Task: 
 This task was chosen because previous studies in this lab using this same task, 
77 
  
and other labs using similar tasks have reliably demonstrated deficits in motor function 
and coordination in rodent models of developmental ETOH exposure (Lewis et al., 2007; 
Thomas et al., 2004).  Thomas and colleagues (2009), showed that offspring exposed to 
ETOH and choline on gestational days (5-20) showed similar levels of performance as 
controls on a motor function and coordination task, while ETOH alone offspring 
performed significantly worse. Because of this we hypothesized that DMXB-A would be 
able to reduce deficits in this task produced by our model of developmental ETOH 
exposure.  
On PND 31-33, offspring were tested on a dowel balance paradigm. The 
apparatus consisted of one dowel rod (114cm long, 1.85cm diameter) that was elevated 
(75cm above the ground). Pads were placed under the dowel to avoid injury in case of 
falling. At the end of the dowel there was a black escape box (21x10x17cm). Before 
testing, each rat was handled for three minutes, weighed, and individually housed in the 
colony room. Testing began the following day and continued for three days (PND 31-33). 
The experimental room for the balance task was illuminated with a red light, a muffin fan 
helped reduce extraneous environmental noise during testing. Before testing, each rat was 
brought into the experimental room and habituated to the room for 10 min. On day 1, the 
subject was placed in the escape box for 1 minute to habituate and then returned to their 
home cage for 30 sec. After habituation, the subject was placed on the dowel 10 cm away 
from the escape box and allowed to enter the escape box. Once the subject successfully 
completed a trial, the distance to the goal box was increased by 13cm. A correct trial was 
defined as reaching the escape box without slipping or falling. An incorrect trial was 
defined as a subject slipping (two or more paws falling off the dowel) or falling off the 
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dowel completely. Once the animal reached the escape box it was left in the escape box 
for an additional 10 sec. The subject was then returned to their home cage for 30 sec until 
the next trial began. During the first trial of test days 2 and 3 the animal was placed on 
the dowel 13 cm further than their last successful distance traveled on the previous testing 
day. Total distance traveled on the dowel rod was the dependent measure for this task. 
Once a rat completed the three trials for that day, the dowel was cleaned with 30% ETOH 
before the next subjects were tested. 
Hebb Style Water-Maze 
 This task was chosen because previous studies in this lab using this same task, 
and other labs using similar tasks have reliably demonstrated deficits in spatial navigation 
and working memory in rodent models of developmental ETOH exposure (Lewis et al., 
2011; Thomas et al., 2009; Hunt et al., 2009). Lewis and colleagues demonstrated that 
offspring exposed to ETOH in the same manner as the current study required 
significantly more trials to complete the task on the second day of testing. Also, Thomas 
and colleagues (2004) demonstrated in a similar maze, the Morris Water Maze (a 
paradigm that requires offspring to use spatial navigation and working memory), that 
prenatal ETOH exposure reduced performance compared to controls and concomitant 
choline treatment reduced these deficits. Because of this we hypothesized that DMXB-A 
would be able to reduce deficits in this task produced by our model of developmental 
ETOH exposure. 
 The maze was a 130 x 90 x 40 cm black Plexiglass chamber divided into multiple 
divergent paths, with each path 18 cm wide (Fig. 1) The end of the maze was 
characterized with a submerged platform approximately 1cm below the water. The water 
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was mixed with non-toxic black powder tempura paint to obscure the platform. The 
temperature of the water in the maze was kept at 76 degrees +/-  2 degrees F and 
temperature of the room was 75 degrees +/- 3 degrees F. A plastic sheet surrounded the 
maze to reduce potential external cues from surroundings and the experimenter. The 
performance of the offspring was recorded by the experimenter and SMART real time 
video tracking software (San Diego Instruments). Testing was conducted between PND 
40-45 for two days; day 1 was termed acquisition day and day 2 was termed retention 
day. One day prior to testing, each rat was handled for 3 min and weighed. On day 1, 
subjects were habituated to the test room for 5 minutes prior to the start of testing. For 
each trial, the rat was placed at the start of the maze. The rat’s swim path was recorded 
until it reached the platform or after a 1 minute ceiling had passed (resulting in a failed 
attempt). If the rat failed to reach the platform on a given trial, it was guided to the 
platform by hand. The rat was allowed to stay on the platform for 10 seconds at which 
time it was removed from the maze and placed in a holding cage under a heat lamp until 
the next trial commenced.  
 This task required thee correct left/right discriminations. A correct trial required 
reaching the platform with no errors.  The learning criterion was defined as two 
consecutive trials with zero errors with a ceiling of 20 trials. At the conclusion of 
acquisition training, the rat was left under the heat lamp for 5min to warm up/dry off and 
then returned to its home cage. The maze was cleaned before the next subject begins 
testing. For day two, the retention period, the same procedure was used as day one.  
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Attentional Set-Shifting Task (ASST): 
This task was chosen because individuals with prenatal ETOH exposure 
commonly have deficits in executive function including reduced ability to shift 
attentional sets and ability to inhibit responses and make more errors (McGee et al., 2008; 
Riley et al. 2011; Jones et al., 2011). These deficits in executive function have also been 
found in animal models of developmental ETOH exposure (Kingdon et al., 2016). 
Previous studies using a similar task have shown that administration of an α7-nAChR 
agonist can both reduce deficits in an animal model of schizophrenia and improve 
cognitive flexibility in control offspring (Wood, et al., 2016). Recently, choline 
supplementation after prenatal ETOH exposure improved deficits in a set-shifting task 
very similar to the task used in the current study (Waddell et al., 2017).   
Testing began on PND 50-55. In this paradigm offspring had to differentiate 
between odor and media to receive food reward. The apparatus was approximately 35 x 
60 cm with one side containing a dividing wall were on each side (17.5cm) a cup 
containing the scent and media was placed. A start gate was placed between the animal 
and the two sides to stop exploration until a trial begins. 
One week before testing began, offspring were placed on a restricted diet in order 
to reach a body weight of approximately 80-85% of their free-feeding weight. Once the 
offspring reached the desired weight day 1 training could begin. On day 1 of training 
offspring were first shaped to the task of digging in unscented cups for a food reward (1/2 
of a cheerio). The unscented media was wood chips, similar to that found in the 
offspring’s home cage. After 10 successful trials of digging and retrieving the food 
reward the animal was then tested on two forms of simple discrimination. For the first 
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simple discrimination (SD1) the animal was tasked with differentiating between two 
scents (garlic or dill) and one media (wood chips). This discrimination was done in order 
to determine if the animal could properly distinguish between scents without the 
distraction of different medias. An additional simple discrimination (SD2) was completed 
after the first where the animal was tasked with differentiating between two different 
media’s (beads or rubber bands) with the same scent (celery) in order to receive food. 
This discrimination was completed to determine whether the animal could properly 
distinguish between media without the distraction of scent. For each simple 
discrimination the selection of only one scent (garlic or dill for SD1) or one media (beads 
or rubber bands for SD2) resulted in food reward. For the first four trials the animal was 
allowed to explore both cups in order to find the food reward. For all remaining trials the 
first cup the animal explored, whether it had a food reward or not, will end the trial.  
Criterion for completion during these and all following discrimination tasks was six 
correct trials not including the initial four exploratory trials. When the animal completed 
both SD1 and SD2 they could move on to day 2 testing.  
 During day 2 testing the animal was tasked with attending to one of two scents or 
media in the presence of both. This phase of testing explored their ability to shift between 
these different scent or media sets.  Testing was comprised of six total components 
including complex discrimination (CD), CD reversal (CDR), interdimensional shift (ID), 
ID reversal (IDR), extradimensional shift (ED), and ED reversal (EDR)(See Table. 3.1). 
During the CD phase offspring attended to a scent (paprika or nutmeg) while ignoring the 
media the scents were in. To ensure the offspring were not attending to the media 
multiple sets of cups were made that had each scent in both types of media. During 
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testing these media/scent combinations were randomly assigned so the animal could not 
predict which media the rewarding scent would be in. The side of the rewarding scent 
was also randomized. For CD Reversal the scent that the animal was attending to was 
switched to the opposite scent. The media remained the same in this phase. This reversal 
challenged subjects to inhibit the learned response to attend to a previously rewarded cue 
and instead shift to the other now rewarded cue. As described above, for all day two 
phases offspring were allowed 4 initial trials to explore both cups and following these 
trials the offspring first choice would end the trial. The animal needed to complete six 
correct trials in a row after the initial four exploratory trials to meet criterion to go onto 
the next phase. During the ID and ID reversal phases, testing was the same to that of CD 
and CD reversal except that both scents and media were different. During ED and ED 
reversal, like in the other phases, two new scents and media were used, however the 
animal was only rewarded for attending to media instead of scent which challenged 
offspring to inhibit previous attentional strategies and adapt to new cue sets to receive 
reward.  
Statistical Analysis 
The data were analyzed using SPSS analysis of variance (ANOVA) with either a 
univariate or repeated measure where appropriate. Unless stated otherwise, the milk and 
NTC groups were compared first for similarity; if they showed no significant variation 
they were then collapsed into a single control group. This was done because the NTC 
group was used to investigate the effect of intubations, if no significant variation was 
found between the two groups it was assumed that intubation itself had no meaningful 
effect and these offspring could be considered control. Combining the control and NTC 
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groups also allows direct investigation of potential interactions between our compound 
and ETOH in a 2 x 2 analysis. Variables included sex (2), x ETOH (2) x drug (2).  
Subsequent ANOVAs were based on the interactions from this overall analysis.   If there 
was no main effect or interaction with sex, the data was collapsed across this variable for 
ease of presentation.  Significant main effects were broken down when needed using 
Least Significant Difference (LSD) post hoc analyses.  All tests were investigated for 
outliers and litter effects before statistical analysis, for this study no offspring were 
removed from analysis and there were no significant differences between litters regarding 
performance. Significance for all analyses was set at p<0.05. 
Results 
Open-Field Performance: 
 Group performance was investigated using total distance traveled for each day 
and distance traveled for each 5-minute time block for each day. The first 5 minutes of 
each day was also investigated as a measure of reactivity to initial placement into the 
chamber. Entries into the center and percentage of time spent in the center of the chamber 
was also investigated because this is a common measure for impulse control (lack of 
inhibition).  
 Overall there were no significant differences between the groups in the open-field. 
Our hypothesis that ETOH offspring would be more active than control offspring and that 
treatment with Solidago nemoralis (SN) could reduce that increased activity was not 
supported. Also, as predicted, SN alone had no effect on performance.  
Total Distance Traveled: 
 A 2 x 2 x 2 x 2 (Sex x ETOH x SN x day) repeated measure ANOVA revealed no 
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significant interactions or main effects between any of the groups. Because of the a-priori 
hypothesis and previous work in this lab, we predicted that ETOH offspring would be 
more hyperactive than control offspring and a LSD post-hoc analysis was used to 
investigate potential group differences. No differences were found between the groups for 
either day. (Fig. 3.1) 
 Total Distance Traveled by Day and 5 Minute Time Block: 
The sex x ETOH x SN x day x block (2 x 2 x 2 x 2[6]) analysis using a repeated 
measures ANOVA also showed no significant interactions or main effects. However, 
because of previous findings in this lab an a-prior hypothesis that groups would differ 
based on treatment group, an LSD post-hoc analysis was run and confirmed the previous 
analysis that there was no significant difference between any of the groups (Fig. 3.2 & 
3.3) 
Total Distance Traveled in the Center: 
A 2 x 2 x 2 x 2 (Sex x ETOH x SNx day) repeated measure ANOVA revealed a 
similar pattern specifically that there were no significant interactions or main effects 
between any of the groups or group differences as assessed by an LSD post-hoc analysis, 
ETOH exposed offspring had increased variability in time spent in the center for day 1 
when compared to controls, however this difference was not significant. This was not 
observed in offspring treated with both SN and exposed to ETOH (Fig. 3.4).  
Total Distance Traveled by 5 Minute Time Block in the Center: 
Again, sex x ETOH x SN x day x block (2 x 2 x 2 x 2[6]) repeated measures 
ANOVA revealed similar pattern as total distance, specifically that there were no 
significant interactions or main effects and not significant differences between any of the 
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groups as assessed by LSD post-hoc analysis. However, ETOH offspring performance 
toward the end of day 1 testing appeared more active compared to controls, but this 
difference was non-significant (Fig. 3.6). This increase in activity was not observed in 
offspring treated with SN after ethanol exposure (Fig. 3.5) 
Entries into the Center: 
 A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x Day) repeated measures ANOVA 
revealed that there were no significant interactions or main effects for entries into the 
center of the apparatus. An LSD post-hoc investigating individual group differences also 
revealed no significant difference between any of the group for either day.  (Fig . 3.7) 
Percentage of Time Spent in the Center: 
A 2 x 2 x 2 x 2 (Sex x ETOH x DMXB-A x Day) repeated measures ANOVA 
revealed that there were no significant interaction or main effects. An LSD post-hoc 
analysis confirmed that none of the groups differed on either day (Fig. 3.8) 
Balance Performance: 
 Treatment with SN in ETOH exposed offspring resulted in no significant 
differences between this group and control animals. Offspring exposed to ETOH alone 
had significantly reduced performance below that of control animals for a single trial in 
day three, however ETOH offspring’s performance for the reminder of the trails was 
similar to that of control animals. A 2 x 2 x 2 x 3(3) repeated measures ANOVA (sex x 
ETOH x SN x day[trial]) was conducted and yielded a main effect of ETOH 
F(1,101)=4.245, p<.05. Group differences were investigated using a LSD post-hoc 
analysis, offspring exposed to ETOH performed more poorly than control offspring 
during the first trial of day 3 (p<.05), when treated with SN, performance in ETOH 
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offspring was similar to that of control animals (see Fig. 3.9). The greatest distance 
achieved was also investigated (Fig. 3.10) and no significant differences were found. 
Water Maze Performance: 
 In support of the hypothesis, SN treatment in ETOH exposed males significantly 
reduced the number of trials required to reach criterion compared to males exposed to 
ETOH alone during acquisition. This trend continues into retention where both SN alone 
and SN treatment in ETOH exposed males require significantly less trials to reach 
criterion than males exposed to ETOH alone.  In females, there is a trend for the ETOH 
exposed offspring to require more trials to reach criterion during acquisition that is not 
present in any of the other groups. No differences were found during retention in females.  
 A 2 x 2 x 2 x 2 (sex x ETOH x SN x day) repeated measures ANOVA revealed a 
main effect of sex F(1,90)=5.212, p<.05, and a main effect of SN F(1, 90)=5.988, p<.05. 
Because of this each sex was investigated separately. In males, a 2 x 2 x 2 (ETOH x 
DMXB x day) repeated measures ANOVA revealed a main effect of SN F(1,46)=7.746, 
p<.01. Group differences were explored using LSD post-hoc analysis. Males exposed to 
ethanol and treated with SN took fewer (p<.05) trials to reach criterion than ethanol alone 
offspring during both acquisition and retention.  Also, males treated with SN alone 
required significantly less trials to reach criterion than ETOH offspring during retention 
but did not differ from control offspring (see Fig. 3.11). In females, the 2 x 2 x 2 ANOVA 
revealed no interactions or main effects. Though not significant, there was a trend for the 
ETOH exposed females to require more trials to reach criterion than any other group 
during acquisition (see Fig. 3.12).  
Attentional Set-Shifting Task Performance: 
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 Because of the multifaceted and complex nature of the ASST task, each phase of 
testing was unique and thus warranted investigation using a univariate ANOVA between 
ETOH, SN, and sex (2 x 2 x 2) (see Wood et al., 2016 & Hawkey, 2017). Additionally, 
trials to criterion and number of errors made during trials will be discussed separately 
because they are different measures investigating how long it takes to learn an attentional 
set (rodent demonstrates greater cognitive ability if they require less trials to acquire a 
new attentional set) and how well the animal can inhibit previous learning (the more 
errors made implies more difficulty inhibiting previously learned attentional sets) 
(Waddell et la., 2017; Gursky & Klinstova 2017). Each main effect and interaction will 
be provided in sequential order by phase (starting with SD1 and ending with EDR when 
applicable). Also, with subsequent analyses, because an a-prior hypothesis that groups 
would differ in performance based on treatment group, an LSD post-hoc analysis was 
used to investigate group differences.  
Trials to Criterion: 
In support of our hypothesis, ETOH exposed offspring required more trials to 
reach criterion than control offspring in several phases. This was particularly true in 
female offspring. Treatment with SN in ETOH exposed offspring reduced the number of 
trials to criterion to control levels in every phase that ETOH exposed offspring displayed 
deficits. However, SN alone increased the number of trials required to reach criterion 
during simple discrimination, a phase that was unaffected by ETOH exposure alone, in 
male and female offspring and complex discrimination reversal in males.  Treatment with 
SN in ETOH exposed males also increased the number of trials required to reach criterion 
during both simple discrimination trials, while ETOH alone had no effect.  
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Because there was a difference between male and female offspring for several of 
the phases including a main effect of sex for the first simple discrimination 
F(1,79)=3.686, p<.05, and an interaction between sex and SN during complex 
discrimination reversal F(1,79)= 5.816, p<.05, the results for each sex will be presented 
separately for ease of presentation.  
In males, for the first simple discrimination (SD1) there was a main effect of SN, 
F(1,39)=7.221, p<.05 and no interactions. An LSD post-hoc analysis revealed that males 
treated with SN and SN and ETOH both required significantly more trials (p<.05) to reach 
criterion than control offspring during SD1. For the second simple discrimination (SD2) 
there was a main effect of ETOH, F(1,39)=6.358, p<.05 and no interactions. For this 
phase, an LSD post-hoc analysis revealed that males exposed to ETOH and treated with 
SN required significantly more (p<.05) trials to reach criterion than control offspring. 
Additionally, those treated with ETOH alone appeared to require more trials during SD2 
than controls, though this difference was not significant, there were no other group 
differences. For the complex discrimination (CD) phase there were no main effects or 
interaction, however, an LSD post-hoc test revealed that ETOH exposed males required 
significantly more (p<.05) trials to reach criterion than controls during this phase and 
treatment with SN in ETOH animals reduced this deficit to control levels. For complex 
discrimination reversal (CDR) there were also no main effects or interactions, however 
an LSD post-hoc analysis revealed males treated with SN alone required significantly 
more (p<.05) trials to reach criterion than control offspring, however, this effect was not 
seen in ethanol exposed offspring treated with SN. For all other phases, including 
89 
  
Intradimensional shift (ID), ID reversal (IDR), extradimensional shift (ED), and ED 
reversal (EDR) there were no main effects or interactions for males.  (see Fig. 3.13) 
 For females, there were no significant main effects or interactions for the first 
simple discrimination (SD1). LSD post-hoc analyses revealed that females treated with 
SN required significantly more (p<.05) trials to reach criterion than controls, however, 
this group did not differ from either ETOH or ETOH + SN offspring during this phase.  
For the second simple discrimination (SD2) there were no main effects or interaction. For 
complex discrimination (CD) there was a main effect of ETOH, F(1,41)=4.321, p<.05, 
SN, F(1,41)=7.142, p<.05, and an interaction between ETOH and SN, F(1,41)=5.822, 
p<.05. An LSD post-hoc analysis revealed that females exposed to ETOH required 
significantly more trials (p<.005) than controls to achieve criterion during this phase and 
that treatment with SN reduced this deficit to control levels. For both complex 
discrimination reversal (CDR) and Intradimensional shift (ID) phases there were no main 
effects or interactions. However, ETOH exposed offspring, though not significant, 
performed similarly to previous phases and required additional trials to reach criterion for 
both of these phases.   During the intradimensional reversal (IDR)  and extradimensional 
shift (ED) phases there were no main effects, however, an LSD post-hoc analysis 
revealed that females exposed to ETOH during both of these phases required more trials 
(p<.05) than controls to reach criterion and that treatment with SN reduced these deficits 
to control levels. Finally, during extradimensional reversal (EDR) there were no main 
effects or interactions.  (see Fig. 3.14) 
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Errors: 
 Our hypothesis was supported in that offspring exposed to ETOH made more 
errors than control offspring during several phases. Treatment with SN in ETOH exposed 
offspring reduced this deficit in some of the phases affected but did not reduce this in 
others.  
Again, because there was a difference between male and female offspring for 
several of the phases including an interaction between sex and SN for complex 
discrimination (CD) F(1,79)=4.058, p<.05, for complex discrimination reversal (CDR) 
F(1,79)= 4.723, p<.05, and for extradimensional shift (ED) F(1,79)=4.976, p<.05, the 
results for each sex will be presented separately for ease of presentation.  
 In males, for the first and second simple discrimination phases (SD1 & SD2), 
there were no main effects or interactions in errors made during these phases. For 
complex discrimination (CD), there was a main effect of ETOH, F(1,39)=6.264, p<.05, 
and an interaction between ETOH and SN, F(1,39)=9.108, p=.005. An LSD post-hoc 
analysis revealed that all three treatment groups (ETOH, SN, and ETOH + SN) made 
more errors (p<.05) than control offspring during this phase. However, those treated with 
SN alone and in addition to ETOH, though not significant, were closer to control 
performance than those treated with ETOH alone.  For complex discrimination reversal 
(CDR) there were no main effects or interactions, however LSD post-hoc revealed a 
significant increase (p<.05) in errors in males treated with ETOH compared to controls. 
For Intradimensional shift (ID), ID reversal (IDR), extradimensional shift (ED), and ED 
reversal (EDR) there were no main effects or interactions. (see Fig. 3.15). 
 In females, for the first simple discrimination (SD1), there was a main effect of 
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ETOH, F(1,41)=4.092, p=.05, and an LSD post-hoc analysis revealed that females 
exposed to ETOH, and those exposed to ETOH and treated with SN made more mistakes 
(p<.05) than controls. However, differences between groups in amount of errors made are 
in the order of 1 which may be statistically significant though biologically insignificant 
for complex animal behavior.  For the second simple discrimination (SD2), there were no 
main effects or interactions, however LSD post-hoc analysis revealed that females 
exposed to ETOH and treated with SN made more mistakes (p<.05) than controls. For 
complex discrimination (CD) there was a main effect of SN, F(1,41)=4.204, p<.05, and 
an LSD post-hoc analysis revealed there were no differences between the controls and 
any of the other groups, however, ETOH exposed females made significantly more errors 
than SN treated females. For complex discrimination reversal (CDR) there were no main 
effects or interactions. For Intradimensional shift (ID) there was a main effect of ETOH, 
F(1,41)=5.025, p<.05, and an LSD post-hoc analysis revealed that females exposed to 
ETOH made more errors than control offspring during this phase. For Intradimensional 
shift reversal (IDR), extradimensional shift (ED), and extradimensional shift reversal 
(EDR) there were no main effects or interactions. (see Fig. 3.16)   
Body Weights: 
For all tasks weight was recorded after the completion of each behavioral test.  
For open-field weights were recorded on PND 21 and analyzed with neonatal treatment 
and sex as grouping variables (see Table 3.2). As predicted, a 2 x 4 ANOVA revealed a 
main effect of both sex F(1,100)=28.873, p<.01, where males generally weight more than 
females of the same group, and treatment group F(1,100)=71.592, p<.01 but no 
interaction. Post-hoc analysis revealed that both male and female offspring treated with 
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ETOH and ETOH & DMXB-A weighed less than control offspring (p<.05). For balance 
the ANOVA revealed a main effect of sex F(1,101)=11.930, p<.005, where males 
consistently weighed more than females, and a main effect of group F(1,101)=7.414, 
p<.005, where both ETOH and ETOH + SN offspring weighed significantly less than 
control offspring. This was true in both male and female offspring. For water maze the 
ANOVA revealed a main effect of sex F(1,90)=191.647, p<.001 and a main effect of 
group F(1,90)=4.591, p=.005, and no interaction. Males, as predicted, were reliably 
heavier than their female counterparts in all groups. Additionally, ETOH males weighed 
significantly less than their respective control offspring, also ETOH females treated with 
SN weighed significantly less than their respective control offspring. For the ASST task 
the ANOVA revealed a main effect of sex F(1,78)=35.434, p<.001 and no interaction. 
Males, as predicted, were reliably heavier than their female counterparts in all groups. 
There was no longer an effect of ETOH exposure on weight during ASST.   
Discussion: 
 This study was aimed at determining if SN could reduce the behavioral deficits 
produced by developmental ETOH exposure during the 3rd trimester brain growth spurt in 
rodents. In short, SN appeared to reduce some of the deficits found in motor coordination, 
learning/memory, and executive functioning.  However, these results appeared to be 
dependent on sex, and in some cases SN alone, or in combination with ETOH was 
detrimental to behavior. These results are explored further below.  
 As discussed previously, previous research in this lab and others have 
demonstrated that developmental ETOH exposure, particularly during the third trimester, 
can impair behaviors related to attention/hyperactivity (Smith et al., 2012; Thomas et al., 
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2007; Lewis et al., 2012), learning/memory (Hunt et al., 2009; Thomas et al., 2009; 
Tiwari et al., 2012), coordination/balance (Idrus et al., 2011; Lewis et al., 2007; Thomas 
et al., 2004), and executive function (reviewed in Gurskey & Klinstova 2017).  Along 
with these deficits in behavior, this period is also sensitive to anatomical deficits in 
regions associated with these behaviors including the cerebellum, hippocampus, and 
prefrontal cortex are undergoing great growth and development during the third trimester 
and are more sensitive to ETOH’s teratogenic effects (for review see Dobbing & Sands, 
1979; Riley & McGee, 2005 & Patten et al., 2014). These areas are innervated by the 
cholinergic system and contain α7-nAChR’s (Hurst et al., 2013). Previous studies have 
demonstrated the potential of α7-nAChR activation to reduce behavioral deficits 
associated with various neurological disorders including developmental ETOH exposure 
(Yu et al., 2012; Koukouli & Maskos, 2015; Suzuki et al., 2006, Thomas et al., 2016). 
Because of this we believed SN, a plant derived flavonoid extract that targets the α7-
nAChR would be able to reduce the behavioral deficits associated with developmental 
ETOH exposure.  
The first test offspring were ran in was an open-field task. This task was used in 
the current study because like humans, animals who are exposed to ETOH during 
development typically demonstrate inattention/hyperactivity (for review see Mattson et 
al., 2011 & Patten et al., 2014). In the current study however, our hypothesis was not 
supported, and offspring exposed to ETOH did not display the typical pattern of 
hyperactivity where path length and time spent in the center of the apparatus was 
significantly increased over control offspring. Because there was no effect of ETOH in 
this task the addition of SN by itself and in ETOH exposed offspring could not be 
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properly investigated for group differences.  Previous studies in this lab using identical 
methods and exposure model (Lewis et al., 2012; Smith et al., 2012) and other labs who 
have used similar models (Thomas et al., 2007 & 2016) have reliably found that ETOH 
animals are more hyperactive/inattentive than control animals. It is unclear why 
performance in this paradigm would be any different from performance in previous 
studies from the same lab, but it did not appear to be an outlier or litter effect. When 
considering possible explanations for lack of an ETOH effect average activity in control 
offspring was compared between this study and previous studies in this lab, for Smith et 
al., (2012), average activity was approximately the same as the current study (around 
2000 cm. total distance traveled for both days). Interestingly, they did not find an effect 
of ETOH on total distance traveled for day 2 in respect to control performance, but 
ETOH did increase entries into the center of the apparatus for both days. As mentioned 
previously, investigations into the BAC’s for this model have been performed and it has 
shown that this model produces BAC’s up to 220 mg/dl 60 minutes after intubation 
(Lewis et al., 20011). BAC’s in this range have reliably produced deficits in the 
behaviors investigated for this study (see Painter et al., 2014 for review). Future 
investigations using this model with the open-field task should be completed to determine 
a possible cause for this difference because the use of this task is invaluable in 
determining the efficacy of compounds aimed at reducing some of the behavioral effects 
of developmental ETOH exposure.   
 SN was also investigated for its ability to reduce deficits in motor coordination 
after developmental ETOH exposure. As previously discussed, this paradigm was used 
because deficits in coordination (as measured by distance traveled in the current study) 
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are common in both clinical cases and animal models of FAS/FASD (Idrus et al., 2011; 
Lewis et al., 2007; Thomas et al., 2004). This task is believed to be mediated by the 
cerebellum, a structure that is particularly sensitive to the effects of developmental ETOH 
exposure (see Riley & McGee, 2005 for review). This structure is also innervated by the 
cholinergic system and contains α7-nAChR (Hurst et al., 2013). Previous studies have 
shown that activation of the α7-nAChR through choline supplementation have reduced 
deficits in motor function in animals exposed to ethanol during development (Thomas et 
al., 2004 & 2016). In the current study, performance in offspring treated with SN and 
exposed to ETOH was at or near control levels during the entirety of the test. However, 
ETOH exposure alone only reduced performance significantly below control levels 
during a single trial of day three. However, though not significant, ETOH offspring did 
appear to have reduced performance for the remainder of the test. A reduction in deficits 
produced by ETOH exposure as a result of activation of the α7-nAChR agrees with 
previous studies such as Thomas and colleagues (2009) who found that supplementation 
with choline (a α7-nAChR agonist) was able to reduce deficits in motor ability and 
coordination in rodents exposed to ETOH during development.  
 Deficits in learning and memory were also investigated during the current study 
using a Hebb style water maze developed by Von Euler and colleagues (2006). This test 
is unique in that it demonstrates learning (acquisition of the task) and memory (retention 
of the task) in just two days. The use of a paradigm investigating learning and memory is 
useful because clinical populations with FAS/FASD often demonstrate deficits in these 
abilities (Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012). In the current study, 
males treated with SN after ethanol exposure required significantly less trials to reach 
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criterion than offspring exposed to ethanol alone during both acquisition and retention. 
Additionally, treatment with SN alone in males significantly reduced the trials required to 
reach criterion below that of offspring treated with ethanol during retention. Though not 
significant, a similar pattern was observed in females during acquisition where ETOH 
exposed offspring took more trials to reach criterion than control or SN treated ETOH 
exposed offspring. These results support the hypothesis that a single dose of SN during 
EWD can reduce learning and memory deficits using this model of ETOH exposure. 
Thomas and colleagues (2009 & 2016) have supported the role of activating the α7-
nAChR through choline supplementation in reducing learning and memory deficits in 
other water maze tasks. However, this is the first study to use this task to investigate SN’s 
ability to reduce deficits produced by 3rd trimester ETOH exposure followed by EWD. 
Interestingly, there also appeared to be a difference in performance between male and 
female offspring regarding acquisition and retention. Female offspring had no significant 
differences between the groups regarding trials to criterion. Previous studies from this lab 
using an identical model of ETOH exposure and the same task found that animals 
exposed to ETOH only displayed a deficit during acquisition and not retention for both 
male and females (see Lewis et al., 2007 & 2011). However, in the current study males 
appeared to show a deficit in both acquisition and retention after ethanol exposure 
compared to offspring treated with SN and exposed to ethanol, and females showed no 
differences in performance at all. Goodlett & Peterson (1995) suggested that males may 
be more affected by developmental ETOH exposure than females in learning tasks like 
the Morris water maze, which would support the current findings.  
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 SN’s ability to reduce deficits in executive function after developmental ETOH 
exposure was also investigated. To study this, we used the attentional set shifting task, 
also referred to as the ASST. ASST is considered to be an animal correlate to the human 
Wisconsin card sorting task (see Barnese et al., 2002), where the participant is expected 
to shift between changing rules for reward. In our task as described above, the animal is 
required to shift its attention from odor to odor or media to media, while ignoring the 
other odor and media cues present to receive reward. Executive function has been shown 
to be deficient in many individuals with FAS/FASD and has also been shown in animal 
models of this disorder as well where deficits appear to be in ability to shift attentional 
sets and ability to inhibit previous learning (for review see Kingdon, Cardoso, & 
McGrath, 2016 & Gurskey & Klinstove 2017).  Performance of this task appears to be 
largely controlled by communication between the prefrontal cortex and striatum (Birrell 
& Brown et al., 2000; Barnese et al., 2002), both structures that contain α7-nAChR 
(Hurst et al., 2013) and are sensitive to developmental ETOH exposure (Barron et al., 
2017; Goodlett et al., 1997; Riley et al., 1993), especially during the third trimester 
(Ikonomidou et al., 2000). These deficits are thought to arise from aberrant connectivity 
from the PFC to other structures critical for the performance of set-shifting like the 
hippocampus (Gorsky & Klinstova 2017). Previous studies using a similar task have 
shown that administration of an α7-nAChR agonist can both reduce deficits in an animal 
model of schizophrenia and improve cognitive flexibility in control animals (Wood, et 
al., 2016). Recently, choline supplementation after prenatal ETOH exposure improved 
deficits in a set-shifting task very similar to the task used in the current study (Waddell et 
al., 2017). However, this task had never been used in our third trimester model of ETOH 
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exposure. In the current study we investigated the number of trials required to complete 
the task (6 trials correct in a row to move to the next phase) and number of errors made in 
each phase. Offspring exposed to ETOH required more trials to achieve criteria and made 
more errors during complex discrimintation (CD) in both male and female offspring, and 
Intradimensional shift reversal (IDR) and extradimensional shift (ED) in females. A 
single administration of SN in ETOH exposed offspring reduced the number of trials 
required to reach criterion to control levels for each of these phases in both male and 
female offspring. Deficits in complex discrimination are common because this is the first 
phase where an animal is required to attend to a specific stimuli (scent) and ignore other 
stimuli (media and unrewarded scent) (Waddell et al., 2017 & Gursky & Klinstova 2017). 
Reversal ability in animals exposed to developmental ETOH also appears to be a 
common deficit (Kingdon et al., 2016). To be able to reverse an animal must be able to 
inhibit response to an old stimuli that was previously rewarded to a newly rewarded 
stimuli (Bissonette et al., 2013), this trouble with response inhibition leading to issues in 
reversal learning are common in individuals and rodents exposed to ETOH during 
development (Kingdon et al., 2016). Deficiencies in reversal learning are believed to be 
mediated by damage to the medial PFC (mPFC), where Mihalick and colleagues (2001) 
found that rodents with a lower number of mPFC neurons (in response to prenatal ETOH 
exposure) were more deficient at reversal learning than control animals. Deficits in 
extradimensional (ED) shifts are also common after developmental ETOH exposure 
(Gurskey & Klinstova 2017). ED shifts test the strength of attentional sets formed for a 
previously rewarded set, which is odor in the present study, an increase in the number of 
trials to complete ED demonstrates a deficit in ability to shift attentional set to attend to a 
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new set (Waddell et al., 2016). Another interesting finding was that males exposed to 
ETOH and treated with SN required significantly more trials to reach criterion during the 
SD1 and SD2 phases, but females exposed to ETOH alone made more errors during these 
phases a result not found in the remaining phases. These initial simple discriminations 
only require the animal to attend to a single stimulus at a time. Previous studies using an 
ASST model similar to our own have found that animals exposed to ETOH are deficient 
in simple discriminations when compared to control (Waddell et al., 2016).  However, the 
current study only found this deficit when ETOH and SN were combined. It’s possible 
that this combination is detrimental for these simple discriminations, however, this deficit 
did not continue in any of the other phases. Also, studies using compounds that target the 
cholinergic system in combination with developmental ETOH exposure have not found 
deficits of this nature (Waddell et al., 2016) Also, in both males and females exposed to 
SN alone, there were times that these offspring required significantly more trials to 
complete the task. Interestingly, SD1 (their first discrimination) was an issue for SN 
offspring for both sexes, this effect was not observed in females for the remaining phases 
but was observed in males during the CDR phase. Again, this is not supported by the 
literature where compounds that target the α7-nAChR have commonly found 
improvement in performance over controls (Wood et al., 2016 & Waddell et al., 2016). 
This difference between control offspring and those treated with SN should be explored 
further to determine if this is a continuing effect or simply due to random variation.  
We also investigated errors made in the ASST task, males exposed to ETOH 
made more errors during complex discrimination (CD) and CD reversal (CDR), and 
females exposed to ETOH made more errors during simple discrimination 1 and 2 and 
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also Intradimensional shift. Again, these deficits in performance were expected due to 
previous findings by Waddell and colleagues (2017). Errors made commonly correlate to 
a difficulty in shifting to a new set, or difficulty inhibiting previous response sets 
(Kingdon et al., 2016). An unexpected finding was that females and males who were 
exposed to ETOH and treated with SN both made more errors during several of the 
phases. However, these differences were not supported by the results of previous 
literature using other α7-nAChR activating drugs (Waddell et la., 2017), and many of 
these differences were less than 1 error which may not be biologically relevant. Again, 
because this is the first time using this task to investigate any compound in our third 
trimester ETOH exposure model it is important to further investigate these potential 
differences between groups to determine if this is an effect of the drug or just a random 
event.  
The present study demonstrates the ability of the flavonoid extract, Solidago 
nemoralis (SN), derived from the grey goldenrod, in reducing some of the behavioral 
deficits produced by “3rd trimester” ETOH exposure in rodents. Though it is clear further 
work needs to be completed with this compound to understand its variable effects on sex 
and the possibility of it producing deficits in certain behaviors, these initial results lend 
evidence to the cholinergic systems involvement in reducing deficits produced by 
developmental ETOH exposure. As discussed above, there are currently no 
pharmacotherapies clinically approved to treat FAS/FASD.  As previously mentioned, 
targeting EWD, a process that is severely damaging to the developing nervous system 
(Riley et al., 2011) is one potential avenue for reducing deficits related to FAS/FASD and 
could be a one-time treatment. The mechanism for the damage caused by EWD, as 
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reviewed above, is thought to be predominately produced by excitotoxicity, oxidative 
stress, and neuroinflammation (Alfonso-Loeches et al., 2011).  SN, an extract rich in 
flavonoids and a compound that has shown affinity for binding at the alpha7 receptor has 
been shown to reduce these types of damage in cellular models of ETOH exposure (Lutz 
et al., 2015).  Because SN was able to reduce some of the behavioral deficits associated 
with developmental ETOH exposure in our model, it appears that agonizing the alpha7 
receptor is a promising avenue for reducing deficits in FAS/FASD. Clearly more work is 
necessary with this compound to further elucidate the differences between treatment 
groups in our behavioral studies as well as to further understand its actions in the nervous 
system. But this is a promising step and the clinical utility of this compound seems 
apparent and should be investigated further in hopes that it or another compound like it 
will one day be used to treat the harmful effects of developmental ETOH exposure in 
human populations.  
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Table. 3.1, Phases of ASST. 
Table. 3.2, Solidago Nemoralis Study Animal Weights 
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Figures: 
 
 
 
Figure 3.1: Open-Field performance as measured by total distance traveled. 
There were no groups differences in distance traveled for either day of the 
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Figure 3.2: Open-Field performance as measured by total distance traveled and broken down 
into 5-minute blocks. Again, there were no groups differences in distance traveled for either 
day of the open-field task. 
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Figure. 3.3: Open-Field performance as measured by total distance traveled in the first 
five minutes of testing for each day. There were no groups differences in distance 
traveled for either day of the open-field task. 
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Figure. 3.4: Open-Field performance as measured by total distance traveled in the center 
of the open-field for each day. Groups did not differ from one another for either day.  
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Figure. 3.5: Open-Field performance as measured by total distance traveled in the center 
of the open-field in 5-minute time blocks for each day. There were no groups differences 
in distance traveled in the center for either day of the open-field task. 
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Figure. 3.6: Open-Field performance as measured by total distance traveled in the 
center of the open-field in the first five minutes for each day. No significant 
differences were found between groups for either day of testing. 
109 
  
 
 
Figure. 3.7: Open-Field performance as measured by entries into the center of the open-
field. No significant differences were found between groups for either day of testing. 
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Figure. 3.8: Open-Field performance as measured by percentage of time spent in the 
center of the open-field  for each day. No significant differences were found between 
groups for either day of testing. 
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Figure. 3.9: Balance performance as measured by distance achieved. On day 3 trial 1 
performance ETOH offspring did not perform as well as Control offspring (p<.05). This 
difference was not seen in ETOH offspring treated with SN. *p<.05, differs significantly from 
  
112 
  
 
 
 
 
 
Figure. 3.10: Balance performance as measured by greatest distance traveled. Though not 
significant, ETOH offspring appeared to have decreased performance compared to controls. A 
difference not seen in ETOH offspring treated with SN.  
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Figure. 3.11: Water Maze performance as measured by trials required to reach criterion. 
During acquisition and retention ETOH offspring treated with SN required significantly fewer 
trials to reach criterion than did ETOH offspring (p<.05). During retention, offspring treated 
with SN alone required significantly less trials to reach criterion than did ETOH offspring.  + 
p<.05, differs significantly from ETOH offspring. 
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Figure. 3.12: Water Maze performance as measured by trials required to reach criterion. There 
is a trend for the ETOH exposed females to require more trials to reach criterion than all other 
groups during acquisition. There were no group differences in performance at the 24 hr 
retention test.  
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Figure. 3.13: ASST performance as measured by trials required to reach criterion. ETOH 
offspring required significantly more trials to reach criterion during the CD phase. SN offspring 
required significantly more trials to reach criterion during the SD1 and CDR phases. offspring 
exposed to both ETOH and SN required significantly more trials to reach criterion during the 
SD1 and SD2 phases. *p<.05, differs significantly from respective control. 
Legend: SD1 & SD2 = simple discrimination, CD & CDR = Complex discrimination & reversal, ID 
& IDR = Intradimensional shift & reversal, ED & EDR = extradimensional shift & reversal. 
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Figure 3.14: ASST performance as measured by trials required to reach criterion. ETOH 
offspring required significantly more trials to reach criterion during the CD, IDR, and ED 
phases. SN offspring required significantly more trials to reach criterion during the SD1 phase. 
*p<.05, differs significantly from respective control. 
Legend: SD1 & SD2 = simple discrimination, CD & CDR = Complex discrimination & reversal, ID 
& IDR = Intradimensional shift & reversal, ED & EDR = extradimensional shift & reversal. 
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Figure 3.15: ASST performance as measured by errors made. ETOH, SN, and ETOH + SN 
offspring made significantly more errors during CD. However only ETOH offspring made 
significantly more errors during the CDR phase. *p<.05, differs significantly from respective 
control. 
Legend: SD1 & SD2 = simple discrimination, CD & CDR = Complex discrimination & reversal, ID 
& IDR = Intradimensional shift & reversal, ED & EDR = extradimensional shift & reversal. 
 
118 
  
 
 
 
 
 
Figure 3.16: ASST performance as measured by errors made. ETOH and ETOH + SN offspring 
made significantly more errors during SD1 and SD2. However only ETOH offspring made 
significantly more errors during the ID phase. *p<.05, differs significantly from respective 
control. 
Legend: SD1 & SD2 = simple discrimination, CD & CDR = Complex discrimination & reversal, ID 
& IDR = Intradimensional shift & reversal, ED & EDR = extradimensional shift & reversal. 
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Chapter 4:  
Overall Discussion: 
This dissertation focused on the ability of two separate compounds (DMXB-A 
and SN) that selectively target the α7 nAChR to reduce behavioral deficits associated 
with “third trimester” ETOH exposure in male and female rodents. Both studies 
demonstrated that these compounds can provide some form of protection from 
developmental ETOH exposure in several of the behavioral paradigms investigated. 
DMXB-A reduced deficits produced by ETOH exposure in motor function in females and 
learning and memory deficits in males. SN reduced deficits produced by ETOH exposure 
in motor function and executive function in both sexes and learning and memory deficits 
in males. These results provide further support for the role of activation of the α7 nAChR 
in reducing the damage associated with developmental ETOH exposure and withdrawal. 
However, with both compounds, it appeared that their effects were sex specific and that 
treatment with the compounds alone, or in combination with ETOH, could produce 
deficits in specific tasks.  
The model of developmental ETOH exposure used in the current studies targeted 
the “brain growth spurt” which co-occurs with the third trimester in humans. An 
equivalent time of rapid brain growth occurs in rodents just before birth and into the first 
postnatal weeks (Dobbing & Sands). Targeting this period of rapid development is useful 
because it is a time where the CNS is particularly sensitive to the teratogenic effects of 
ETOH exposure (Barron et al., 2016; Goodlett et al., 1997; Riley et al., 1993). ETOH 
exposure during this period have reliably produced behavioral deficits in motor 
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coordination (Idrus et al., 2011; Lewis et al., 2007; Thomas et al., 2004), 
attention/activity (Smith et al., 2012; Thomas et al., 2007; Lewis et al., 2012), learning 
and memory (Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012), and executive 
function (Thomas et al., 2000). Along with these deficits in behavior, ETOH exposure 
during this period has also produced anatomical deficits in regions associated with these 
behaviors including the cerebellum, hippocampus, and prefrontal cortex (for review see 
Dobbing & Sands, 1979; Riley & McGee, 2005 & Patten et al., 2014). Currently, no 
clinically approved medication exists to treat these deficits produced by developmental 
ETOH exposure and so development of a compound is critical. ETOH withdrawal is 
believed to mediate a considerable amount of the damage associated with developmental 
ETOH toxicity by producing neurotoxicity, oxidative stress, and neuroinflammation 
(Livy et al., 2003, Painter, et al., 2014; Alfosno-Loeches & Guerri, 2011). Development 
of a compound aimed at reducing the damage associated with EWD during a period of 
rapid brain growth is appealing because it is potentially a one-time treatment that would 
protect the fetus or newborn after ETOH has left the system.  Previous studies have 
demonstrated the potential of α7-nAChR agonization to reduce neurotoxicity, 
neuroinflammation, and oxidative stress (de Jonge & Ulloa, 2007; Prendergast et al., 
2000 & 2001; Li et al., 1999; Suzuki et al., 2006; Wang et al., 2003; Xiu et al., 2005; 
Shytle et al., 2004). Activation of this receptor has also reduced behavioral deficits 
associated with various neurological disorders and developmental ETOH exposure (Yu et 
al., 2012; Koukouli & Maskos, 2015; Suzuki et al., 2006, Thomas et al., 2016). The 
primary hypothesis of the current study was that an injection of DMXB-A or SN, 21 
hours after the animal’s final exposure to ETOH (during a period of withdrawal), would 
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be able to reduce deficits caused by ETOH exposure. Both compounds used in the current 
studies have demonstrated potential in reducing the damage associated with 
developmental ETOH exposure. Data from in vitro studies suggest that DMXB-A dose-
dependently reduced cell death following ETOH exposure in E17 (embryonic) cells, 
PC12 (pheochromocytoma) cells, and in adult male rodents (DMXB-A preexposure 24 h 
prior to ETOH) (de Fiebre et al., 2003; Li et al., 2002; Shimohama et al., 1997; Tizabi et 
al., 2004). Additionally, rhamnetin, a flavonoid found in SN, has demonstrated an ability 
to reduce both neuroinflammation and excitotoxicity in response to EWD in an 
organotypic hippocampal slice culture (Lutz, et al., 2015).  
First, both DMXB-A and SN demonstrated some ability to reduce deficits in 
motor coordination after ETOH exposure, though it appeared to be sex dependent. These 
results were not surprising because many α7-nAChR containing cholinergic neurons 
innervate key structures related to motor coordination and balance like the cerebellum 
(Hurst et al., 2013; Koukouli & Maskos 2015), a structure that is also particularly 
sensitive to the effects of developmental ETOH exposure (Thomas et al., 2004). Thomas 
and colleagues (2009) also found that choline was able to reduce deficits in motor 
function produced by prenatal ETOH exposure. They postulated that one of the possible 
mechanisms that could have produced this effect is α7-nAChR modulation of 
glutamatergic neurons in the cerebellum preventing excitotoxicity during ETOH 
exposure and withdrawal. Previous studies have supported a role in α7-nAChR reducing 
cell damage produced by NMDA-induced toxicity in PC12 cell lines, primary 
hippocampal cultures and in organotypic hippocampal cultures (Prendergast et al., 2000 
& 2001; de Fiebre et al., 2003 & 2005; Yangxin et al., 2002).  This activity is thought to 
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possibly be mediated by activation of the α7 nAChR which is believed to increase 
calbindin-D28K (a calcium buffer) activity which in turn reduces intercellular calcium 
and increases cell survival (Mullholland et al., 2003). Another interesting possibility is 
through cross-desensitization with the NMDAR where activation of the α7 nAChR by 
donepezil hydrochloride appeared to mediate phosphorylation and subsequent 
internalization of specific NMDAR receptor subunits preventing excitotoxicity (Kihara et 
al., 2010). Next, both compounds were able to reduce some deficits in learning and 
memory. Tasks involving learning and memory are mediated by many structures in the 
CNS, namely the hippocampus and prefrontal cortex, both of which are sensitive to 
developmental ETOH exposure (Lebel et al., 2011), and contains α7-nAChR’s (Hurst et 
al., 2013). The reduction of learning deficits in this study are supported by previous 
research demonstrating postnatal choline supplementation was able to rescue deficits in a 
spatial navigation task (the Morris Water Maze) after ethanol exposure during the third 
trimester equivalent in rodents (Thomas et al., 2016).  DMXB-A has also previously 
demonstrated an ability to rescue spatial navigation deficits in the Morris task in rodents 
who had bilateral lesions of the Nucleus Basalis (a structure rich in cholinergic neurons) 
(Meyer et al., 1997). Additionally, DMXB-A was also shown to be neuroprotective 
against global ischemia and glutamate-induced excitotoxicity in rodents while also 
improving cognitive function on a passive avoidance task (Nanri et al., 1998). In this 
study, Nanri and colleagues theorized that this protection against cellular damage and 
cognitive deficits was provided by the α7 nAChR’s reduction of excitotoxicity and 
neuroinflammation. Though they did not give supporting details about this mechanism, 
however, activation of the α7 nAChR has been implicated in reducing these mechanisms 
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of damage (excitotoxicity discussed above). In neuroinflammation, activation of α7 
nAChR’s found on microglia, have been shown to reduce microglial activation and 
reduce LPS-induced TNF-alpha release (Suzuki et al., 2006; Shytle et al., 2004). 
Activation of the α7 nAChR has also been shown to reduced LPS-induced TNF-alpha 
release in an in-vitro model of EWD in the hippocampus of neonatal rodents (Lutz et al., 
2015 a & b). It is believed that activation of the receptor creates a neuroprotective state in 
the microglia and in turn reduces transcription and phosphorylation of critical 
components required for activation of an inflammatory response like nuclear factor 
kappa-b, and mitogen-activated protein kinase (see Lutz, 2015 & Suzuki et al., 2006 for 
review). Finally, SN demonstrated an ability to reduce some of the deficits found in 
executive function produced by ETOH administration. Performance of this task appears 
to be largely dependent on the proper functioning of the prefrontal cortex (Birrell & 
Brown et al., 2000; Barnese et al., 2002), a structure that contains many α7-nAChR 
(Hurst et al., 2013) and is particularly sensitive to developmental ETOH exposure 
(Barron et al., 2017; Goodlett et al., 1997; Riley et al., 1993), especially during the third 
trimester (Ikonomidou et al., 2000). These deficits are thought to arise from aberrant 
connectivity from the PFC to other structures critical for the performance of set-shifting 
like the hippocampus (Gorsky & Klinstova 2017). Previous studies using a similar task 
have shown that administration of an α7-nAChR agonist can both reduce deficits in an 
animal model of schizophrenia and improve cognitive flexibility in control animals 
(Wood, et al., 2016). Recently, choline supplementation after prenatal ETOH exposure 
improved deficits in a set-shifting task very similar to the task used in the current study 
(Waddell et al., 2017). This study stipulated that one of the possible mechanisms of 
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protection provided by choline could possibly be a reduction of NMDA-induced 
excitotoxicity by activation of the α7-nAChR. Again, as discussed above, activation of 
the α7-nAChR leading to decreases in excitotoxicity has been supported by previous 
literature. Though the exact mechanisms of protection provided by the α7-nAChR is not 
well understood, it is clear that this receptor is involved in the modulation of and 
subsequent neuroprotection against processes related to excitotoxicity, oxidative stress, 
and neuroinflammation (for further review see Lutz et al., 2015 & Benchrief et al., 2014).  
Though the two compounds demonstrated potential in reducing deficits associated 
with developmental ETOH exposure, there were also several unexpected findings. One 
unexpected finding was during the assessment for hyperactivity and impulse control in 
the Open-Field chamber. Unexpectedly, there was a lack of ETOH response in the open-
field paradigm for both studies. As mentioned previously, this task was used because like 
humans, rodents who are exposed to ETOH during development commonly demonstrate 
hyperactivity (for review see Mattson et al., 2011 & Patten et al., 2014).  Previous studies 
in this lab using the same model of ETOH exposure and the same task for assessing 
activity levels have reliably found increased activity in offspring exposed to ETOH both 
in overall activity, activity in the center, and entries into the center (Lewis et al., 2011, 
Smith et al., 2012). This hyperactivity in humans and animals, expressed as increased 
path length and entries into the center in the current study, is believed to be caused in part 
by an inability to inhibit responses that may not be appropriate to the situation (Riley et 
al., 2011; Thomas et al., 2009). To explore potential explanations, we considered our 
dose of ETOH. We administer a total of 6 g/kg/day of ETOH (3g/kg twice daily) by oral 
gavage from postnatal days (PND) 1-7. BAC’s for this dose of ETOH peak at 220 mg/dl 
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(+/- 6mg/dl) approximately 60 minutes after intubation (Lewis et al., 2011). This level of 
ETOH exposure has been efficacious in producing behavioral deficits in the open-field 
task, dowel balance rod, and water maze (Lewis et al., 2007 & 2011, Smith et al., 2012). 
We also compared control animal activity in the current study to previous studies in this 
lab. Controls had approximately the same level of activity in both studies (20000 cm +/- 
100)(Smith et al., 2012).  It is also possible that these animals in the current study were 
especially hardy to the effects of developmental ETOH exposure in our model, however, 
this is doubtful due to the homogenous nature of animals used in this study (Sprague 
Dawley), the fact that no litter or outlier effects were detected, and the fact that we have 
reliably found activity deficits in these animals in the past (see above). Future 
investigations in this lab using this exposure model with the open-field task should be 
completed to determine a possible cause for this difference because the use of this task is 
invaluable in determining the efficacy of compounds aimed at reducing the effects of 
developmental ETOH exposure 
An additional unexpected finding was that both DMXB-A and SN appeared to 
have variable effects on performance in several of the behavioral studies. DMXB-A, 
when combined with ETOH, in the open-field task appeared to reduce overall activity but 
increase activity in the center of the apparatus. Though DMXB-A’s effects on this task 
have not been previously investigated in this or any model of ethanol exposure, these 
results were unexpected. As discussed previously, choline, a compound believed to 
activate the α7-nAChR, in combination with ethanol exposure both pre and postnatally 
have reliably produced control levels of activity, while ETOH alone resulted in increased 
activity (Thomas et al., 2004 & 2007).  This behavior is believed to be mediated in part 
126 
  
by the basal forebrain and hippocampus because lesions of these areas have produced 
increases in activity level (for discussion see Thomas et al., 2004). These areas are also 
innervated by nAChR’s, including the α7-nAChR’s. Thomas and colleagues stipulated 
that the reduction of activity level produced by choline in reaction to developmental 
ETOH exposure could possibly be due to activation of the α7-nAChR and its subsequent 
decrease in NMDA-mediated toxicity (Thomas et al., 2004, and discussed above). It may 
be possible that DMXB-A does not provide this type of protection for this specific task in 
response to developmental ETOH exposure, a possibility that has not been explored in 
the literature. But because there is support for the α7-nAChR’s protection of this and 
other tasks against developmental ETOH exposure combined with the fact that we did not 
see the usual ETOH mediated increase in activity in this task leads to the conclusion that 
this result may not be meaningful. However, further work is necessary to address this 
potential issue. DMXB-A in combination with ETOH also appeared to reduce balance 
performance in male animals, a finding that was also unexpected. Again, previous 
literature supports the role of the α7-nAChR in reducing motor function deficits in this 
task (Thomas et al., 2004 & 2009). Also, the combination of DMXB-A and ETOH was 
able to rescue deficits in this task in females in the current study. Interestingly, there were 
no sex differences in any of the groups in Thomas and colleagues (2004) investigation of 
balance deficits produced by third trimester ETOH and subsequent rescue of this deficit 
by choline. Our own lab has found sex differences in performance between male and 
female animals on this task where females generally performed better than male subjects, 
which they believed was produced by differences in body weights (Lewis et al., 2007). 
However, in the current study, though body weights did differ between the sexes for each 
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treatment group, there was no meaningful difference in performance between males and 
females in control groups or those treated with DMXB-A alone. Again, it may be 
possible that DMXB-A does not provide this type of protection for this specific task in 
response to developmental ETOH exposure in males, a possibility that has not been 
explored in the literature. Though there is support for the α7-nAChR’s protection of this 
and other tasks against developmental ETOH exposure, it is clear that this possibility of 
sex specific effects of treatment with DMXB-A in response to developmental ETOH 
exposure should be further investigated. Finally, SN treatment alone and in combination 
with ETOH produced increases in the amount of trials required to reach criterion and 
errors made in several of the phases in the ASST paradigm. Previous studies using a 
similar task have shown that administration of an α7-nAChR agonist (a novel compound 
SSRI180711 [compound-A]) can both reduce deficits in an animal model of 
schizophrenia and improve cognitive flexibility in control animals (Wood, et al., 2016). 
Recently, choline supplementation after prenatal ETOH exposure improved deficits in a 
set-shifting task very similar to the task used in the current study (Waddell et al., 2017). 
However, neither of these studies demonstrated any deficits produced by treatment with 
the α7-nAChR itself, in fact both studies supported the role of these compounds to 
increase performance in certain phases when administered alone. Also, Waddell did not 
find that administration of choline after developmental ETOH exposure increased deficits 
in any of the phases of ASST, instead it only decreased it. However, this is the first time 
this compound has been investigated for its effects to reduce developmental ETOH 
exposure in this task. So, these deficits caused by SN by itself and in combination with 
ETOH may be meaningful which indicates that this possible interaction should be 
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investigated further because previous literature does not support the role of α7-nAChR 
activating compounds reducing performance in this task either by itself or in combination 
with ETOH.  
Another somewhat unexpected finding in several of the studies was that there 
appeared to be a difference in the way males and females responded to both ETOH 
administration and treatment with either compound. As previously mentioned, during the 
DMXB-A study, males appeared to have reduced activity in response to ETOH treatment 
as well as the combination of ETOH and DMXB-A. This result was unexpected because 
ETOH exposure reliably produces increases in activity but not in a sex specific way 
(Lewis et al., 2011; Smith et al., 2012). Also previous studies using a compound that is 
believed to target the α7-nAChR (choline) found that the combination of this drug with 
ETOH resulted in activity being at control levels in both males and females (Thomas et 
al., 2004 & 2009).  As discussed above, this behavior is believed to be mediated in part 
by the basal forebrain and hippocampus because lesions of these areas have produced 
increases in activity level (for discussion see Thomas et al., 2004). These areas are also 
innervated by nAChR’s, including the α7-nAChR’s (Hurst et al., 2013). The mechanism 
of protection provided by activation of the α7-nAChR in this task was theorized to be 
from its reduction in glutamate-induced neurotoxicity (Thomas et al., 2004). Previous 
studies have supported the theory that α7-nAChR activation can reduce glutamate 
toxicity and neuroinflammation in response to ETOH exposure in both male and female 
organotypic hippocampal explants, but this mechanism did not appear to be sex specific 
(Lutz et al., 2015). However, this was the first time DMXB-A was investigated for its 
ability to reduce activity in response to developmental ETOH exposure. There could 
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potentially be an unexplored sex-specific effect produced by this compound in 
combination with ETOH in this model that clearly needs further investigation. Additional 
differences were found in males exposed to ETOH and treated with DMXB-A where they 
had reduced performance on the dowel task, a result not found in females (however this 
difference was discussed at length in the previous section). Another interesting sex effect 
was for both the DMXB-A study and SN study females in the water maze task exposed to 
ETOH performed at control levels, while males exposed to ETOH required more trials to 
reach criterion. For the SN study, males and females differed in water maze performance 
where males, like in the DMXB-A study, treated with ETOH required more trials to reach 
criterion. Studies in this lab using the same methodology and exposure model have not 
previously found sex differences in this task (Lewis et al., 2007 & 2011; Smith et al., 
2012). Other labs investigating developmental ETOH’s effects on similar tasks have also 
not found sex specific differences in response to ETOH exposure (Thomas et al., 2004, 
2007 & 2009; Riley et al., 2005). However, Goodlett & Peterson (1995) suggested 
females performance on spatial navigation tasks (in their case, the morris water maze) 
may be less sensitive to ETOH exposure than males which does support the finding in 
both studies of this dissertation. Additional studies exploring prenatal ETOH exposure in 
wistar rats (Hamilton et al., 2014; Savage et al., 2010) and long-evans rats (Hannigan et 
al., 1987) have also found that males are typically more affected than females in 
navigation tasks. Interestingly, in none of the above studies were the causes for this 
difference explained. As mentioned previously, this task is believed to be mediated 
largely by the hippocampus and prefrontal cortex (Lebel et al., 2011) and these structures 
are particularly sensitive to developmental ETOH administration (Schneider et al., 2011 
130 
  
& Gursky & Klinstova 2017). Waddell and colleagues (2017) found that males were 
more sensitive to deficits in performance on an executive function task that involves the 
use of the prefrontal cortex after prenatal ETOH exposure than females. They postulated 
this was because prenatal ETOH appears to disrupt engagement of the frontal cortices in 
males more than females which could lead to deficits in executive functioning tasks as 
well as learning and memory tasks. With this, it is clear further work needs to be 
conducted to explore the possible difference between male and females in reaction to 
developmental ETOH exposure. Another interesting finding that is contradictory to the 
evidence discussed above is that in the ASST task, females appeared to be more sensitive 
to the effects of ETOH than males were. Again, in the study by Waddell & Mooney 
(2016), they found that males were more sensitive to ETOH’s effects in the ASST than 
females. Perhaps this difference could be because of the timing of developmental ETOH 
exposure (prenatal for the Waddell study and neonatal for the current), however Gursky 
& Klinstova (2017) found that males and females were similarly deficient in executive 
tasks after third trimester ETOH exposure.  It is clear that there are differences between 
males and females in response to ETOH for several of these tasks, and future work in this 
lab or others should investigate these differences further to elucidate the potential 
explanation and mechanism for these differences.  
It appears that both DMXB-A and SN were able to reduce some of the deficits 
associated with developmental ETOH exposure.  However, as discussed throughout this 
discussion there are many things that we do not yet have a clear answer for where future 
investigations in this lab and others who want to understand the role of the α7 nAChR in 
developmental ETOH exposure should address.  For one our compounds at the current 
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dose had variable effects on performance alone and when combined with ETOH. These 
effects appeared to be dependent on sex in several of the tasks. Future studies should 
investigate these compounds effects on microscopic and macroscopic brain structures in 
male and female animals exposed to ETOH during different developmental timepoints to 
see if they produce varied effects in structure or regions associated with behavioral 
deficits demonstrated in the current study like the prefrontal cortex, hippocampus, and 
cerebellum. This could help determine if their effects are varied by region and what role 
sex potentially plays in these differences. As mentioned before, these compounds have 
been investigated for their effects on ETOH exposure and withdrawal in-vitro (de Fiebre 
et al., 2003; Li et al., 2002; Shimohama et al., 1997; Tizabi et al., 2004; Lutz et al., 2015) 
and found that these compounds can increase cell survival produced by various forms of 
damage including neurotoxicity, neuroinflammation, and oxidative stress. However, these 
studies are typically conducted on specific cell lines, or in explants of specific regions of 
the brain like the hippocampus. It would benefit this and other studies using these 
compounds to understand how these specific compounds (or other selective α7 nAChR 
agonists) effect neuronal development in an intact nervous system exposed to ETOH 
during development.  With these types of findings, we could then try to correlate our 
findings in these behavioral studies with changes in the intact brain of male and female 
animals exposed to ETOH during the same developmental period. Future studies may 
also benefit from further investigations into the exact mechanisms in which the α7 
nAChR receptor produces neuroprotection. As mentioned previously, activation of the α7 
nAChR’s found on microglia, when activated, have been shown to reduce microglial 
activation and reduce LPS-induced TNF-alpha release (Suzuki et al., 2006; Shytle et al., 
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2004). Activation of the α7 nAChR has also been shown to reduced LPS-induced TNF-
alpha release in an in-vitro model of EWD in the hippocampus of neonatal rodents (Lutz 
et al., 2015 a & b). This process is believed to occur because the α7 nAChR receptor 
creates a neuroprotective state in the microglia and in turn reduces transcription and 
phosphorylation of critical components required for activation of an inflammatory 
response like nuclear factor kappa-b, and mitogen-activated protein kinase (see Lutz, 
2015 & Suzuki et al., 2006 for review). Modulation of this receptor has also been 
associated with reductions in NMDA-induced toxicity (Dajas-Bailador 2000; Lutz et al., 
2015; Prendergast et al., 2000 & 2001; de Fiebre et al., 2003 & 2005; Yangxin et al., 
2002). This is thought to occur beacause activation of the α7 nAChR increases calbindin-
D28K (a calcium buffer) activity which in turn reduces intercellular calcium and 
increases cell survival (Mullholland et al., 2003). This could also be from activation of 
the α7 nAChR resulting in phosphorylation and subsequent internalization of specific 
NMDAR receptor subunits preventing excitotoxicity (Kihara et al., 2010). However, 
these mechanisms are just theories and a clear answer is not available. What is clear is 
that the protection provided by this receptor is varied and involves many processes. 
Discovering the particular mechanisms that modulate this receptors protection could help 
explain some of the current findings, but more importantly help direct future 
investigation and possibly medication development aimed at reducing the effects of 
developmental ETOH exposure and other neurological disorders.  
Taken together it appears that both DMXB-A and SN can reduce some behavioral 
deficits associated with “3rd trimester” ETOH exposure in rodents. This project lends 
support to the theory that compounds that act as agonists at the nicotinic receptor system, 
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specifically the α7 nAChR, is a promising route to reducing or eliminating ETOH’s 
adverse effects on developing offspring. It also provides justification to further explore 
these or other compounds that target the α7 nAChR in other models of ETOH exposure 
and CNS disease/disorder as well as possibly lead to clinical development of a 
pharmacotherapy to treat FAS/FASD.   
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